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Multidrug resistant (MDR) cancers often become resistant to pharmacologically and 
structurally diverse drugs by overexpressing members of the family of ATP Binding Cassette 
(ABC) transporters. These membrane pumps protect normal cells by actively exporting a large 
range of toxins out of the cells. Classic MDR is often correlated with the overexpression of three 
well-studied mammalian ABC transporters: P-glycoprotein (P-gp), Breast Cancer Resistant 
Protein (BCRP), and Multidrug Resistant Protein 1 (MRP1).  
P-gp is the most studied ABC transporter, and the search for P-gp inhibitors as co-
therapeutics to combat MDR has had little success after decades of studies. We previously used 
high-throughput in silico ligand docking studies and identified drug-like compounds that reversed 
MDR in human cancers cell lines. Other compounds were more recently found that also reversed 
MDR in cancer cells, but interestingly, not all of them were recognized in the biochemical ATPase 
inhibition assays 1, 2. One reason why the biochemical screens did not identify these compounds 
may be that the mouse P-gp homolog used in the biochemical test may be sufficiently different 
from human P-gp, making the mouse protein non-representative. We have established methods to 
successfully incorporate P-gp into membrane nanodiscs with high recovery yields and increases 




yield during purification making it undesirable for further experimentation. A newly constructed 
MDR1 clone, codon-optimized for expression in P. pastoris, was transformed into regular (GS115) 
and high expression (PichiaPinkTM) Pichia pastoris systems in attempts to obtain higher protein 
yield to proceed with further experiments. Both new P. pastoris strains containing human MDR1 
failed to express P-gp. Finally, P. pastoris cells expressing the human wild-type MDR1 P-gp were 
provided by Dr. Ina L. Urbatsch (Texas Tech University Health Science Center). The enzyme was 
successfully purified in our lab. To improve the overall enzymatic activity of P-gp, several lipid 
activation tests and assembly into nanodisc with different lipid content were tested for the 
optimized activity improvement of the protein. P-gp reconstituted into nanodiscs were used to 
evaluate the potential of our newly discovered drug-like compound to serve as inhibitors of human 
P-gp ATP hydrolysis activity.  
Here we also reported our attempts to optimize the expression and purification of BCRP 
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CHAPTER 1                                                                                                                                 
BACKGROUND 
 
1.1 ABC transporters and their role in multidrug resistance in cancer cells 
Multidrug resistance (MDR) is an important phenomenon of significant medical 
consequence in the chemotherapeutic treatment of cancer. It has been linked to the failure of 
chemotherapy, poor prognosis, and reduced survival rates in patients with several cancer types 3-
10 
In MDR, the cancer cells become resistant to pharmacologically and structurally diverse 
drugs 3, 9, 11-13, often by overexpressing members of a family of membrane pump proteins. These 
resistances may be inherent or acquired 9, 10, 14; in that some cancers may develop from tissues that 
naturally express high levels of particular membrane pumps and other cancers that have been 
exposed to one cytotoxic agent develop cross-resistance to a great range of structurally and 
functionally unrelated compounds by the induction of expression of particular membrane pumps 
8, 10, 12, 15.   
MDR can also occur as an intrinsically stable change within the cell, altering the drug’s 
cellular target or increasing repair of the drug-induced damage or activating detoxifying systems 
such as cytochrome P450 12, 16.  Other examples of MDR are the malignant transformation that 
results in defective apoptotic pathways 12, 16-18. These MDRs are potentially achieved without 




The above-mentioned membrane pump proteins usually are responsible for protecting 
normal cells from xenobiotic attack by exporting a large range of toxins out of the cell. 
Unfortunately, in tumor cells, overexpression of these pumps causes MDR by preventing the 
accumulation of cytotoxic drugs in cells 8, 19 by the action of these energy-dependent unidirectional 
drug efflux pumps.   
 
 
Figure 1. 1: Cellular mechanisms of multidrug resistance (MDR)12 
 
Classic MDR is frequently associated with overexpression of the best-studied mammalian 
ATP Binding Cassette (ABC) transporter, P-glycoprotein (P-gp), the product of the MDR1 gene 
in humans. P-gp is constitutively expressed in various normal human tissues implying an important 
role in excreting xenobiotics and metabolites. For this reason, it also results in the increased efflux 
of chemotherapeutics from cancer cells derived from these tissues 12, 15, 19-23.  
1.2 The role of P-glycoprotein in cancer multidrug resistance (MDR) 
P-glycoprotein is responsible for transporting chemotherapeutic drugs and other 




27. One of the most interesting features of P-gp is that it can recognize and transport drugs with a 
wide array of chemical structures, including a large variety of hydrophobic compounds with 
neutral or positive charge 3, 20, 21, 28. 
P-gp in humans is a 170-kD plasma membrane protein of 1280 amino acid residues, 
expressed from the multidrug resistance protein 1 (MDR1) gene, as a member of the ABC 
transporter family, subclass ABCB1 3, 22, 29, 30.   A molecular model of P-gp protein generated in 
our lab is shown in figure 1a 31.  P-gp exists as a single polypeptide that contains two 
transmembrane domains (TMDs), with six transmembrane α-helices each, and two nucleotide 
binding domains (NBDs). It can be seen as divided into two relatively symmetrical halves 
connected by a linker peptide and presenting a TMD1-NDB1-TMD2-NBD2 topology (Fig. 1 b) 12, 
32-37. The drug binding sites (DBS) for transport substrates are formed by the interaction of the 









Figure 1. 2: The P-glycoprotein structure 
(a) A molecular model of P-glycoprotein generated by McCormick JW, Vogel PD, Wise JG. 
Biochemistry 2015 31. On the left, NBD is open to the inside of the cell conformation, while the 
TMDs are closed to the outside. On the right, the NBDs are in closed conformation while the 
TMDs are wide open to the outside. In red and blue solid spheres, two P-gp substrates are shown 
that seem ready to be released from the proteins on the extracellular side of the cell. (b) Topological 
model of P-gp showing the two homologous halves, each with a TMD containing six TM helices 
and one NBD. From Sharom et al., 201136. 
 
The NBDs and the TMDs of P-gp and other ABC transporters appear to undergo very large 
conformational changes during the catalytic cycle 45-52. Based on crystal structures of homologs in 
various conformations 45, 53-55, targeted molecular dynamics studies of human P-gp were performed 
by Wise 33 to elucidate catalytically relevant structures of P-gp and its conformational changes. 
Transitions from conformations wide open to the cytoplasm to conformations wide open to the 
extracellular space were studied 33. Some previous structural models showed closed NBD dimers 
with nucleotides bound at each site while the TMDs are opened to the exterior of the cell 54-56. At 
the same time, in nucleotide-free structures, the TMDs are disengaged and sometimes widely 
separated. According to Senior & Bhagat 57, two non-simultaneous ATP hydrolysis events are 
needed to transport one drug molecule. Firstly, the binding of the transport substrate to the 




conformational change that releases the substrate 58. Then the hydrolysis at the second ATP site 
reset the transporter allowing it to bind substrate again and completing one catalytic cycle 59. In 
the studies by Wise 33, the coupled movement of NBDs and TMDs observed may support the 
hypothesis that ATP hydrolysis is stimulated in the presence of drugs that are transported. 
According to previous studies 60, 61, inactivation of one NDB blocks the ATP hydrolysis and the 
drug transport  51, 52, 61-63, suggesting that P-gp requires the energy from ATP binding and 
hydrolysis in both NBDs to drive drug transport across the membrane 33, 60, 64, 65. McCormick et 
al.. 31 used the chemotherapeutic daunorubicin and the antihypertensive agent verapamil, both P-
gp substrates, in simulation experiments to observe transport substrate movements cytoplasmic to 
extracellular positions. Although both drugs were docked within the cytoplasmic leaflet part of the 
cell membrane, there was a preferred binding of each substrate to different subsites within the drug 
binding domain (DBD) of P-gp in the open to the cytoplasmic conformation: Daunorubicin 
preferentially bound to residues on TM helices 1, 2, 3, 6, and 11 and verapamil mainly used 
residues on TM helices 4, 5, 6, 7, 8 and 12. The two different drug transport pathways  observed 
in these experiments suggested that there was not only one single defined path of contact that 
drives a transport substrate out of the cell 31. The understanding of the catalytic mechanism of P-
gp is critical to the development of inhibitors that might overcome the MDR 33.  
P-gp has been investigated as a pharmacological target for improving cancer treatment 
since its discovery. For a review, see 66. Inhibiting P-gp as a method to reverse MDR in cancer 
patients has been studied extensively, but despite three decades of effort, it has had relatively little 





1.3 The search for P-glycoprotein inhibitors 
P-gp requires ATP-hydrolysis in the NBDs to catalyze the transport of a broad range of 
compounds across the plasma membrane and out of the cell 28. Although transport substrate 
appears to bind to multiple binding sites within the TMDs, most of the P-gp substrates are 
hydrophobic, suggesting that partitioning into the lipid membrane may be a rate-limiting step for 
the interaction of a substrate with the active site of P-gp 67.  
Many P-gp inhibitors previously identified as potential co-therapeutics for MDR diseases, 
described in Binkhathlan 3, 9, 16, have failed in clinical trials 3, 16. Many of these inhibitors were 
found to compete for binding with the drug transport substrate in the DBDs of P-gp as its transport 
substrate. For this reason, high concentrations are needed for efficacy, likely contributing to 
toxicities that limited the success in clinical trials 16. Besides these problems, several of these 
agents were also good substrates for CYP3A enzymes, the most abundant group of the cytochrome 
P450 (CYP) metabolizing enzymes responsible for catalyzing many reactions involved in drug 
metabolism. This characteristic would likely alter the pharmacokinetics of other drugs, i.e., co-
administered cancer chemotherapeutics 3, 68, 69.  
Many studies have shown that drug binding to the TMDs stimulates ATP hydrolysis in the 
NBDs 33, 64, 65, 70. Since substrate transport is ATP dependent, inhibition of the power source of the 
transporter is thought to stop the catalytic cycle preventing the efflux pump-out activity. Brewer 
et al.. 70 hypothesized that molecules that strongly interact with ATP binding domains of P-gp or 
disrupt nucleotide binding but do not bind well to the DBDs would make better drug leads for 
inhibiting P-gp reversing MDR than those previously investigated. 
Identifying potential inhibitors that would interact with the NBDs of P-gp, the targeted 




in human P-gp during its transition from one conformational state to another during the catalytic 
transport cycle. One specific conformation of P-gp that corresponded to a structural conformation 
of P-gp where the NBDs are fully engaged, and the DBDs were partially open outward was initially 
chosen as a protein target for docking analysis 70.  In general, docking studies can predict the 
preferred orientation of one molecule towards a macromolecule when they are bound to each other 
to form a stable complex 71. High-throughput computational screens of a very large database of 
drug-like molecules from the ZINC website 72, 73 were employed to identify the best predicted hit 
compounds for the in silico docking experiments 70. Using this new computational hit discovery 
approach, with the chosen human P-gp structural conformation, ~ 300 compounds were identified 
that were predicted to bind preferentially to the NBD but not  well to the DBD of P-gp  70.  Initially, 
35 of these compounds (numbered 11-45) were purchased and tested in in vitro biochemical assays 
for the capability to stimulate or inhibit ATP hydrolysis activity by purified P-gp 70. These steady-
state assays utilized a coupled enzyme assay described in 74 and adopted 96 well format as 
described in 70.  
The spectroscopic activity assay for ATP hydrolyzing enzymes described in 70, 74, 75 couples 
the hydrolysis of ATP by P-gp to the oxidation of NADH to NAD+ through reactions of pyruvate 
kinase (PK) and lactate dehydrogenase (LDH). This assay was adapted from 74. ATP hydrolysis 
by P-gp was stimulated by the transport substrate verapamil, a calcium channel blocker. Verapamil 
inhibits the P-gp catalyzed transport of other substrates by competing for the transport cycles 3. 
Low levels of P-gp unstimulated ATP hydrolysis (basal activity) can be observed with hydrolysis 
assays performed in the absence of transportable substrates. In Brewer et al. 70, compounds that 
did not stimulate basal ATP hydrolysis and inhibited verapamil-stimulated ATPase activity were 




achieved the desirable condition of inhibiting verapamil stimulated ATP hydrolysis by P-gp 70. In 
contrast, they did not stimulate basal hydrolysis rates at either ATP concentrations tested, 
suggesting no interactions with DBDs 70. 
Electron spin resonance (ESR) studies were then performed to confirm whether these four 
compounds interacted with the NBDs of P-gp 70. ESR is a very sensitive spectroscopic technique 
that detects species with unpaired electrons, taking advantage of their magnetic moments. Its 
surroundings modify the magnetic behavior of the electron. Biological samples usually lack 
paramagnetic species, and so they are silent in ESR spectroscopy. Fortunately, this lack of 
naturally occurring radicals allows the site-specific attachment of stable radicals, spin-labels (SL), 
as reporter groups to larger molecules and have been used by our group to study multidrug 
resistance proteins 75, 76. The method is highly sensitive to conformational changes occurring 
within the vicinity of these spin-labels, thus providing important information about the structural 
environment of the label and dynamic conformation processes during substrate binding and often 
during enzymatic turnovers 75-78. Titration experiments using a spin-labeled analog of ATP 79 were 
used in 70 in equilibrium binding studies to determine whether the compounds affected ATP 
binding to P-gp. Undefined mixtures of spin-labeled ATP and spin-labeled ADP are called SL-
ANP.  The protein-bound SL-ANP and free SL-ANP have different well-resolved ESR spectra 
allowing the measurement of the concentration of the protein-bound SL-ANP and the dynamics 
and conformational properties of P-gp under compound inhibition conditions 70, 76. The ESR 
studies in 70 showed that compounds 19, 34, and 45 indeed affected nucleotide binding by P-gp 
and, together with inhibitor docking results, suggested that the inhibitors interacted directly with 




caused inhibition of ATP hydrolysis, possibly by blocking crucial conformational transitions of 
the enzyme 70. 
The evaluation of these four P-gp inhibitors to elucidate their potential as pharmaceutical 
lead compounds was reported in 80. The intrinsic cytotoxicity and ability to re-sensitize an MDR 
prostate cancer cell line were assessed. Compounds 29, 34, and 45 restored paclitaxel sensitivity 
in the MDR prostate cancer cell line 80. These compounds were also shown to reverse MDR caused 
by P-gp over-expression in ovarian and colon cancer cell lines (unpublished). The success of these 
inhibitors in cell culture demonstrated that the in silico subtractive screening methods employed 
and the subsequent biochemical and biophysical evaluation have great potential to identify 
potential drug-like compounds as P-gp inhibitors. In work not yet published (manuscript in 
preparation), additional compounds from enhanced in silico screens demonstrated a similar 
reversal of MDR in prostate cancer cell lines. However, some of these compounds did not affect 
ATP hydrolysis when assayed using mouse P-gp (encoded by the mouse MDR3 gene) that had all 
cysteines mutated to alanines (cysteine-less protein). This mouse P-gp is significantly more stable 
than the human homolog 81, and its expression in yeast and subsequent purification was well 
established in the lab.  
Co-crystal structures and molecular dynamics studies, with or without substrates and 
inhibitors, have provided a glimpse of the interactions between some bound inhibitors and the drug 
binding sites 33, 45. Still, much work remains for a full understanding of the molecular mechanism 







The search for P-gp inhibitors as co-therapeutics to combat MDR has had relatively little 
success despite decades of effort. High-throughput in silico ligand docking studies were used by 
us to identify a number of drug-like compounds as potential inhibitors 70. Biochemical assays 70, 
74, 76, 83 using purified P-gp provide important information regarding the mechanism of inhibition 
and have been used as a primary screen in our drug discovery process. 
After the successful reversal of the multidrug resistance phenotype in human cell culture 
assays using molecules identified by these procedures 80, biochemical assays, previously made 
using the mdr3 cysteine-less mouse P-gp, need to be performed also in MDR1 human P-gp 
incorporated into nanodiscs. We hypothesize that the comparison between results obtained with 
these two P-gp variants will help elucidate whether important differences between mouse and 
human P-gp exist and how these differences might affect the interpretation of previous results.  
Interestingly, not all the compounds that reversed MDR in cell culture were recognized in 
these biochemical screens using the mouse P-gp (Chen et al., unpublished). One difficulty in these 
studies was to stabilize and maintain the activity of the protein in the presence of our potential 
inhibitors. We, therefore, established methods to incorporate mouse P-gp into lipid nanodiscs 84, 
85, providing a native-like phospholipid bilayer environment. The reconstitution of this P-gp (the 
cysteine-less mouse P-gp mutant, “mdr3-Cl”) into nanodiscs resulted in enhanced ATPase activity 
and increased stability of the enzyme. We predict that similar stabilization by nanodiscs can be 
achieved using human MDR1 P-gp. In this project, we show the attempts to establish protocols to 
reconstitute human P-gp into nanodiscs. Human MDR1 P-gp is well known for its great instability 
when removed from its native environment. Elucidating methods for its stabilization (i.e., 




may reverse MDR in cancer chemotherapies. Here we also report the evaluation of the potential 
of our previously discovered drug-like compounds to serve as inhibitors of human P-gp ATP 










CHAPTER 2                                                                                                                 




The most studied of the ABC transporters is  P-glycoprotein (P-gp). P-gp is expressed in 
many tissues throughout the human body3-10 and is known to export a diverse range of chemicals 
and toxins from the cell, preventing chemotherapeutics from accumulating to the concentration 
required to kill cancer cells9-13, 23. The search of P-gp inhibitors as co-therapeutics to combat MDR 
has had little success so far in producing clinically applicable drugs11, 14-16. In our lab, we had 
previously used high-throughput in silico docking studies using a molecular model of the human 
P-gp. We were able to identify drug-like compounds that reversed MDR in human cancers 1, 70, 80. 
Expression of P-gp in the yeast Pichia pastoris in a biologically active form was previously 
reported by others and our previous works45, 63, 70, 76, 86 87. Brewer et al.70 were able to test the 
inhibitory effect of those initial compounds on the ATPase hydrolysis activity by purified mouse 
P-gp. At the same time, assays of MDR-reversal of a prostate cancer cell line were made by Follit 
et al. 80, and assays in an ovarian cancer cell line were performed by Nanayakkara 1. More recently, 
computationally identified compounds were shown to reverse MDR in cancer cells and needed to 
be biochemically tested on isolated P-gp (McCormick et al., unpublished). 
For the biochemical evaluation of the newly found compounds, relatively large amounts of 




because the requirement of their solubilization to maintain the target protein in a stable and 
functionally active state allows purification, biochemical and biophysical assays, and structure 
determination85.  
Previous works reported differences in P-gp ATPase hydrolysis activity in the absence or 
the presence of lipids 86. As native membrane proteins are found embedded in a lipid environment, 
this variation observed on the ATPase activity of purified P-gp could be due to different intrinsic 
lipid content on different preparations.  
Traditionally, membrane proteins have been solubilized using detergents to form mixed 
detergent-protein-lipid micelles. Detergents, however, are often protein denaturants and can 
destabilize the protein. In addition, the presence of excess micelles potentially interferes with many 
assay procedures 84, 85, 88, 89.  Membrane proteins can also require specific types of phospholipids 
to maintain active function, making detergent micelles a poor membrane mimetic 84, 85. 
Liposome’s preparations have been used to incorporate membrane proteins90. However, 
liposomes are large and often form unstable aggregates and are difficult to prepare with precisely 
controlled characteristics. Another issue is that membrane proteins can insert into liposomes in 
two different orientations, and surfaces facing the lumen of the vesicle will likely be inaccessible 
to ligands 84, 85. Many membrane proteins interact with ligands or other proteins on one or both 
sides of the membrane 84; with liposome preparations, as much as half of the proteins of interest 
(assuming random orientation of the protein in the membrane) will have little or no possibility to 
interact with other molecules and ligands. For this reason, mixed-micelles or liposomes do not 
always provide the ideal environment for active membrane proteins.  
Nanodiscs are soluble disk-shaped nanoscale phospholipid bilayers which self-assemble 




nanodisc preparation, when detergent is removed, the target proteins assemble with phospholipids 
and an encircling amphipathic protein belt formed by two units of a protein called membrane 
scaffold protein (MSP) (fig. 1). The diameter of the MSP belt will control the overall nanodisc size 
84, 85, 89.  
The resultant nanodiscs allow solubilization of membrane proteins and offer advantages 
over liposomes or detergent micelles not only in terms of size and stability, but the native-like 
phospholipid bilayer environment also provides ready access to both sides of the phospholipids.  
This novel tool gives means to investigate dynamics and molecular mechanisms between the 
protein and membranes, besides protein and its substrate 85. 
 
 
Figure 2.1: Schematic view of nanodisc assembly.   
Modified from 91. Nanodisc assemble from a mixture of detergent/phospholipid micelles and MSP 








2.1.1 Mouse P-gp purification and nanodisc assembly optimization 
In our lab, we have an Mdr3 cysteine-less clone that expresses relatively large amounts of 
the protein. We obtained the GS115 P. pastoris strains expressing human cysteine-less mdr1 from 
Dr. Alan E. Senior (University of Rochester Medical Center, Rochester, New York).  
We established methods to incorporate this mouse P-gp into lipid nanodiscs 84, 85 providing 
the native-like phospholipids bilayer environment to stabilize purified enzyme for our drug finding 
and mechanistic studies (Chen and de Oliveira et al., manuscript in preparation). 
The purification of the P-gp transporter encoded by the modified, cysteine-less mouse 
MDR3 gene was previously optimized and is described in 70, 75.  Further optimizations provided a 
high yield of a relatively pure enzyme from the cysteine-less mouse P-gp (Fig. 2a) suitable for its 
assembly into nanodiscs (Fig. 2b). 
To increase the stability of the P-gp mutants for biochemical and biophysical analyses, we 
have established methods to incorporate (mouse) P-gp into membrane nanodisc successfully and 
were able to reconstitute the P-gp mouse cysteine-free mutant into membrane nanodiscs as 






Figure 2. 2: “Cysteine-free” mouse P-gp (mdr3 Cl) nanodisc assembly and activity summary. 
(a) SDS-PAGE Coomassie blue-stained from purified MDR3Cl. Lane 1: purified mouse MDR3Cl 
P-gp. Lane 2: PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa 
(ThermoFisher ScientificTM). (b) SDS-PAGE Coomassie blue-stained from purified MDR3Cl 
assembled into Nanodisc (two different preparations - Nano 1 and Nano 2). Lanes 1 and 7: Flow-
through recovered, concentrated, and 8 µl were applied for PAGE analysis. Lanes 2 and 6: Column 
Wash was recovered, concentrated, and 8 µl was applied for the PAGE analysis. Lanes 3 and 5: 
Final elution containing the purified mouse P-gp assembled into nanodiscs was recovered, 
concentrated, and 1µl was applied for the PAGE analysis. Lane 4: Spectra™ Multicolor Broad 
Range Protein Ladder PageRuler™, 10 to 260 kDa (ThermoFisher Scientific TM).  Excess 
of MSP can be observed on the bottom of the gel. 
 
The reconstitution of mouse mdr3 cysteine-less P-gp mutant into nanodiscs resulted in 
enhanced ATPase activity, and increased stability of the enzyme showed in Table 1. The maximum 
protein reconstitution yield of the purified mouse P-gp into nanodiscs was 82%, the amount of P-
gp that was assembled into nanodisc from the initial P-gp presented on the assembly mix (P-gp in 
micelles, MSP and L-alpha-phosphatidylcholine). The specific activity increased by 10-fold for 
stimulated activity (Table 1). ATP hydrolysis activity summary in Table 1 is presented as a 








Table 2. 1: ATP hydrolysis activity summary.  






Drug Stim. activity 
(nmol/min/mg) 
P-gp in micelles - 18 110 
P-gp in nanodiscs 1 74% 490 830 
P-gp in nanodiscs 2 82% 570 1190 
 
 
2.1.2 Human MDR1 cysteine less purification 
We obtained the GS115 P. pastoris strains expressing human cysteine-less MDR1 from 
Dr. Alan E. Senior (University of Rochester Medical Center, Rochester, New York).  
Our original purification procedures 70, 75, 76, 86 that had been optimized for mouse mdr3 
cysteine-less P-gp were unfortunately not as efficient when applied to the isolation of human P-gp 
from our existing MDR1 Cl clone (Fig. 3). P-gp losses were observed during all purification steps 
(Figs. 3a and 3b). Even after increased solubilization cycles, the same pattern of enzyme losses 
were observed. Changes in the Ni-NTA equilibration buffer and solubilization buffer (pH 7.4 to 







Figure 2. 3: Human “cysteine-less” P-gp (MDR1 Cl) purification steps.  
(a) SDS-PAGE Coomassie blue-stained from two MDR1Cl purifications. Lanes 1 and 7: Flow-
through recovered, concentrated, and 8 µl were applied for PAGE analysis. Lanes 2 and 6: Column 
Wash was recovered, concentrated, and 8 µl was applied for the PAGE analysis. Lanes 3 and 5: 
Final elution containing the purified human cysteine less P-gp was recovered, concentrated, and 
1µl was applied for the PAGE analysis. Lane 4: Spectra™ Multicolor Broad Range Protein Ladder 
PageRuler™, 10 to 260 kDa (ThermoFisher Scient ificTM).  (b) Western blot analysis from 
each fraction of the purification steps, 10ug protein/well, C219 anti-P-gp antibody (ALX-801-002 
– Enzo Life Science). Lane 1: Elution 1. Lane 2: Elution 2. Lane 3: Column wash 1. Lane 4: 
Column wash 2. Lane 5: Flow-through 1. Lane 6: Flow-through 2.  
 
 After several attempts, the best results were achieved after increasing the detergent/lipid 
ratio during the first solubilization step. The modified pH of the elution buffer was also maintained. 
One hypothesis why poor purification was achieved was that the affinity to the histidine tag on P-
gp for the Ni-NTA resin used was weak. To test this hypothesis, HisPur cobalt resin (Thermo 
Fischer Scientific) was used instead of Ni-NTA. The cobalt-chelated resin performed better than 
Ni-NTA Agarose (Qiagen), presenting somewhat cleaner protein after the second wash was 
applied, as assessed by the SDS-PAGE Coomassie blue gel (see figure 4). Western blot analysis 




However, HisPurTM Cobalt resin (Thermo Fischer Scientific) seemed to result in somewhat cleaner 
protein in fewer steps (in case of additional washes were necessary) than what was achieved by 
Ni-NTA agarose (Qiagen). 
 
 
Figure 2. 4: MDR1 Cl P-gp purification Ni-NTA resin versus Cobalt resin.  
(a) SDS-PAGE Coomassie blue-stained from two MDR1Cl purifications using different gel resin: 
On the left is Ni_NTA agarose (Qiagen), on the right is HisPurTM Cobalt resin (ThermoFisher 
ScientificTM). Lanes 1 and 9: Flow-through recovered, concentrated, and 3 µl were applied for 
PAGE analysis. Lanes 2 and 8: Column Wash 1 was recovered, concentrated, and 3 µl were applied 
for the PAGE analysis. Lanes 3 and 7: Column Wash 2 was recovered, concentrated, and 3 µl were 
applied for the PAGE analysis. Lanes 4 and 6: Final elution containing the purified human cysteine 
less P-gp was recovered, concentrated, and 3 µl was applied for the PAGE analysis. Lane 5: 
Spectra™ Multicolor Broad Range Protein Ladder PageRuler™, 10 to 260 kDa 
(ThermoFisher ScientificTM).  (b) Western blot analysis from each fraction of the purification 
steps, 10ug protein/well, C219 anti-P-gp antibody. Each lane is correspondent with the lane 
presented on the Coomassie blue gel above.  
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However, even after the improvements of the purification procedure, still, more wash steps 
would be needed to obtain acceptably pure protein at reasonable overall protein yields for further 
biochemical studies of the protein.  It seemed clear that the clone available in our lab was not 
providing enough starting material of the human P-gp to proceed with nanodisc assembly. Further 
modifications were made during all the steps starting from yeast growth to protein purification to 
obtain higher expression of this transporter. Still, none was successful enough to yield sufficient 
human P-gp for nanodisc incorporation. However, it seemed to us that the lack of success in this 
task made it necessary to investigate the construction of a more optimized MDR1 clone to achieve 
protein yields high enough for biochemical evaluation.  
 
2.3 Methods and materials 
2.3.1 Growth of P. pastoris mouse MDR3CL P-gp and human MDR1CL P-gp:  
Cells were grown using the methods previously described in 70, 75, 76, 86. In short, a single 
colony of the modified yeast strain grown on a Minimal Dextrose (MD) agar plate (1.34% Yeast 
Nitrogen Base (YNB), 4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 ml of 
liquid Minimal Glycerol (MG) medium (1.34% YNB, 1% glycerol, 4x10-5% Biotin) and incubated 
at 28oC with shaking to OD600 of ~2.0 (18h). After 16-18 hours, this 10 ml was added to 1 liter of 
MG medium in a 2-liter Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 
was continued (~18h), then the cultures were centrifuged in sterile bottles (4000 rpm for 20 min at 
23oC). Protein production was induced by switching the carbon source of the medium from 
glycerol to methanol. The cells pellets were resuspended in 1 liter of Minimal Methanol (MM) 
medium (1.34% YNB, 4x10-5% Biotin, 0,5% v/v methanol) in 2-liter Fernbach flasks covered with 




hours.  The pH was adjusted to ~6.0 at these times. Cells were collected by centrifugation at 4000 
x g for 10 min at 4oC and resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3 
M Tris-HCl, pH 7.4, 1  mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at 
a concentration of 1g wet cells/ml buffer. The cells were stored at -80oC. 
2.3.2 Microsome preparation from yeast cells:  
Microsomes were prepared essentially as described in 86, with the modifications made in 
70, 75, 76. Frozen cells were rapidly thawed by incubating the frozen cells in a water bath set at 28-
30oC for ~10 min, swirling the bottle's content to equilibrate the temperature. All further steps 
were performed at 4oC or on ice. Protease inhibitors were added once the cell suspension was 
thawed as follow: 2 µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml 
PMSF (phenylmethylsulfonyl fluoride), and 10 µl/ml DTT (dithiothreitol). All the cells were 
transferred to a chilled bead beater apparatus that was filled to top with “buffer A1” (30% v/v 
glycerol, 50 mM Tris-HCl, pH 8, 125 mM NaCl, 10 mM imidazole) supplemented with DTT (10 
µl/mL) Cells were mechanically disrupted by using 0.5 mm glass beads in a bead-beater (BioSpec) 
for a total of 14 minutes. The bead-beater was attached to a jacketed chamber filled with an ice-
salt mixture that helped maintain the lower temperature. Cell disruption was performed in 7 cycles 
of 2 minutes bead beating alternated with 6 minutes with the bead-beater “off” to allow cells to 
cool down. This method helped solve the problem of overheated samples due to the high heat 
output of the bead-beater motor. The homogenate was then centrifuged for 30 minutes at 10,000 
rpm (at Beckman J21-M equipped with a JA-20 rotor), and the pellet was discarded. These steps 
removed unbroken cells, nuclei, and mitochondrial fractions. The supernatant was centrifuged at 
45,000 rpm (at Beckman Optima LE-80K equipped with Ti70 or Ti55.2) for 45 min at 4oC. After 




resulting pellet containing the microsomes was resuspended in “wash buffer” (20% v/v glycerol, 
50 mM Tris-Cl, pH 7.4 at 4oC, and protease inhibitors – 1 mM PMSF, 1 mM DTT, Pepstatin A, 
Leupeptin, and Chymostatin as above). The microsomes were recentrifuged at 45,000 rpm at 
Beckman Optima LE-80K equipped with Ti 70 or Ti 55.2) for 45 min at 4oC.  The supernatant was 
discarded, and the pellet was resuspended initially using a paintbrush then by ten strokes by hand 
in a Potter-Elvehjem Teflon pestle homogenizer in 30 ml of “buffer A1” plus protease inhibitors 
as before). The microsomes were then frozen at -80oC.  
2.3.3 P-gp Purification: 
  Purification of the transporter protein was performed essentially as described in 70, 75, 76, 86, 
which successfully resulted in highly enriched mouse (mdr3-Cl) P-gp in mixed micelles. The 
microsomes were quickly thawed in a circulating water bath set at 28-30oC and then eluted to a 
final concentration of 4mg microsomal protein/ml with “buffer A2” (20% v/v glycerol, 50 mM 
Tris-HCl, pH 8.0 at 4oC, 50 mM NaCl, 10 mM imidazole, plus protease inhibitors as follow: 2 
µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 1 mM PMSF). Further dilution of 
the sample to a final concentration of 2 mg microsomal protein/mL was achieved by adding a 
volume of buffer A2 equal to a total volume of the first dilution supplemented with 1.2% (w/v) n-
dodecyl-β-D-maltoside, DDM (Inalco), and 0.02% (w/v) lyso-phosphatidylcholine, Lyso-PC 
(Lipoid GmbH). DDM and lyso-PC were added to facilitate micelle formation, providing a more 
native-like environment during the purification process. Sonication of samples at 4oC for 4 cycles 
of 5 minutes each in an ultrasonic bath filled with ice/water, interspersed with 5 minutes incubation 
in an ice bucket on a rocking platform, was performed to allow protein solubilization. The 
suspension was then centrifuged at 20,000 rpm for 30 min at 4oC (Beckman Optima LE-80K 




applied to the pre-equilibrated Ni-NTA agarose resin (Qiagen) column at a ratio of 100 mg 
microsomal protein per 1ml packing resin (one bed volume). The chromatography gel and 
solubilized protein solution were mixed and incubated for 10 minutes before the column was 
poured. The flow-through was ~2ml/min. The resin with bound P-gp was washed first with 20 
bed-volumes of “Column wash buffer 1” (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC, 
50 mM NaCl, 20 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 % 
(w/v) lyso-PC/mL buffer), followed by 10 bed-volume of “Column Wash buffer 2” (20 % glycerol 
(v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC, 50 mM NaCl, 40 mM Imidazole, supplemented with 5 µL 
20% (w/v) DDM/mL buffer; 1 µL 10 % (w/v) lyso-PC/mL buffer). For both washes, the flow-
through was ~1ml/min.  P-gp was then eluted with 3 bed-volumes of Elution buffer (20 % glycerol 
(v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC, 50 mM NaCl, 300 mM Imidazole, supplemented with 5 
µL 20% (w/v) DDM/mL buffer; 1µL 10 % (w/v) lyso-PC/mL buffer) with a ~0.5 ml/min flow 
rate. All eluted protein was collected for the next step.  To obtain concentrated P-gp, the elution 
fraction from the Ni-NTA column was concentrated 70- to 100-fold using Amicon centrifugal 
filters (Amicon/Millipore Corp., catalog number UFC910008) a molecular mass cutoff of 100,000 
Da. This procedure enriched both protein and micelles and ensured retained solubilization of the 
membrane protein, resulting in concentrated, enriched, and solubilized protein for use in nanodisc 
assembly. The protein was aliquoted in 40µl aliquots, ready to be used in nanodisc assembly, and 
stored at -80oC.  
2.3.4 Nanodisc Assembly and Recovery 84, 85:   
P-gp in mixed detergent micelles obtained during protein purification was assembled with 
Membrane Scaffold Protein (clone available in our lab expressed on BL21 (DE3) E. coli strain), 




mM Tris-CL (pH 8). The detergent was removed using Bio-beads SM, HisPur Ni-NTA 
chromatography was used to isolate nanodiscs, using “start buffer” (20% (v/v) glycerol, 50 mM 
Tris-CL pH 7.5 at 4oC, 50 mM NaCl), and elution buffer (20% (v/v) glycerol, 50 mM Tris-Cl pH 
7.5 at 4oC, 50 mM NaCl, 300 mM imidazole). 
2.3.5 Assays of ATPase activity – Coupled-enzyme assay 70:   
The activity assay for ATP hydrolyzing enzymes developed by Vogel & Steinhart 74 was 
well established and adapted to medium-high-throughput conditions on 96-well plates 70. The assay 
couples the hydrolysis of ATP by P-gp to the oxidation of NADH to NAD+ through the reaction 
of pyruvate kinase and lactate dehydrogenase. The desired amount of Pgp (10 µg or more) was 
added to 1 ml of cocktail (50 mM Tris-Cl, pH 8, 24 mM MgSO4, 1.94 mM PEP, 20 mM KCl, 
0.058 mg/ml Pyruvate kinase (PK), 0.028 mg/ml Lactate Dehydrogenase (LDH), 0.13 mM NADH, 
0.4 M ATP) +/- 150 µM verapamil in DMSO (the same volume DMSO alone was added to the 
control reaction when verapamil was added to the protein samples) at 37oC. ATP hydrolysis was 
recorded as absorbance decrease at 340 nm (ε=6300 M-1 cm-1), using a BioTek plate reader 
(BioTek, Winooski, VT). 
 
2.4 Discussion 
Several studies 82, 86 as well as our lab have reported on the expression of P-gp in the yeast 
Pichia pastoris and purified the protein in what was assumed to be a fully biologically active form. 
P. pastoris yeast grows to very high densities in fermenter cultures, often providing ample source 
material.  
Biochemical assays using purified P-gp provide important information regarding the 




In our previous work 70, the purified mouse mdr3-Cl P-gp variant in micelles was used to 
identify the first set of MDR reversing compounds and investigate the mechanism underlying the 
inhibition. We have successfully tested the effect of potential P-gp inhibitors on P-gp ATPase 
hydrolysis activity.  
 As demonstrated by others 86, the intrinsic lipid content of each preparation could interfere 
with the ATPase hydrolysis activity of P-gp, which we hypothesize could change the way such 
inhibitors would affect P-gp ATPase activity. With this idea in mind, we have established methods 
to incorporate successfully (mouse) P-gp into membrane nanodisc (fig. 2b), with a recovery yield 
of P-gp reconstituted in nanodiscs around 82%, a dramatic increase in the specific basal activity 
of the enzyme and up to 10-fold increase on the specific substrate stimulated activity showing a 
significant increase in stability (table 1).   
This successful approach brought us an optimistic possibility of testing more compounds 
that were being computationally screened at that time. Some of these newly found compounds 
were found to reverse MDR in cancer cells but were not recognized the same way in the 
biochemical screenings (Chen et al., unpublished). One reason why the biochemical assay did not 
identify these compounds may be that even though human and mouse P-gp share about 87% 
identity in amino acid sequence, there may still be sufficient differences between the two proteins 
that may prevent a mouse mdr3-Cl from faithfully reporting on inhibitor action on the human 
protein45, 61, 82, 87.  
Our next approach was to replace the mouse mdr3-Cl P-gp for a human MDR1 cysteine-
less variant also available in the lab. Since we were previously able to optimize the procedures for 




able to improve the yield of its reconstitution into nanodiscs with enhanced ATPase activity and 
increased stability, we decided to repeat our successful protocol this time.  
Unfortunately, the same procedures did not show the same efficacy on the human MDR1 
cysteine-less clone available in our lab (Fig. 3). After a series of modifications of the procedure 
which attempted to optimize conditions for human P-gp purification (altered detergent ratios, pH 
of the chromatography buffer, testing of affinity His-tag- binding to Ni- versus Co resins), and 
even after all modification and finally no significant loss of the protein during the purification, 
each preparation presented very modest final protein yield available from this clone that would not 
support the amount of purified transporter needed for the nanodisc assembly and the following 
biochemical assays (Fig. 4). The low protein yield during purification made it undesirable for 
further experimentation. Bai et al. 82 suggested that codon usage bias may be one of the factors 
leading to inefficient translation in Pichia, thereby limiting protein production.  A codon usage 
adjusted sequence of mouse P-gp-encoding mdr3 gene resulted in a significant increase in P-gp 
expression 82. A high protein expression system seemed desirable to provide the required protein 
yield to proceed with these studies. We hypothesize that a gene for human P-gp that has been 
optimized for translation in Pichia pastoris will allow higher levels of protein expression than 
observed using human DNA sequences for P-gp.  
CHAPTER 3                                                                                                                                
THE CHALLENGES OF LARGE-SCALE PRODUCTION AND PURIFICATION OF THE 
ABC TRANSPORTER P-GLYCOPROTEIN (P-gp) IN THE YEAST, PICHIA PASTORIS. 
 
3.1 Introduction 
3.1.1 Recombinant P-glycoprotein 
Over the last decades, researchers have learned how to manipulate DNA to identify, move 
and place genes into a variety of organisms other than its original source organism and have used 
these techniques mainly to produce proteins that were difficult to otherwise obtain 94, 95. 
Escherichia coli has been the “factory” of choice for the expression of many proteins. Still, 
as it is a prokaryote, it lacks the intracellular organelles and their associated post-translational 
modification activities of eukaryotes. The endoplasmic reticulum and the Golgi apparatus are 
responsible for posttranslational modifications of many eukaryotic proteins (such as glycosylation) 
that may be important for protein function. For this reason, researchers have also turned to 
eukaryotic yeast species for protein production 94, 95. 
Pichia pastoris is a yeast, and therefore a eukaryote offers many of the advantages of 
eukaryotic expression systems, such as protein processing and folding and the availability of 
posttranslational modifications. Pichia pastoris can use methanol as its sole carbon source. The 
utilization of methanol in the absence of glucose or glycerol induces expression from the alcohol 
oxidase (AOX1) promoter, causing the expression of the gene that codes for the alcohol oxidase. 




of expression of alcohol oxidase has been used to genetically link the expression of a protein of 
choice in several readily available expression systems.  
Despite these advantages, a series of limitations and disadvantages of the P. pastoris 
system have been gradually uncovered over the last 20 years:  
1) The expression vectors designed to integrate into the Pichia chromosome may enable 
stable expression but with very low transformation efficiencies because the vector must 
both enter the cell and integrate into specific locations in the host chromosome, both of 
which are inherently inefficient processes 94, 100-103. 
2) Proteases are secreted in the medium during Pichia fermentation, allowing the 
degradation of the desired protein 102. 
3) After the transformation of P. pastoris, lower expression levels than desired may be 
observed in the transformants 102. 
4) Most of the alcohol oxidase activity in the cell is attributable to the AOX1 gene. Still, 
in some transformants, a second gene, AOX2, may be used, which is harder to induce 
using methanol at a much slower rate 82, 104-106. 
Previously, we had expressed different versions of human P-gp and a mouse homologous 
protein in Pichia pastoris (Invitrogen, GS115 strain 98) and purified the protein in a biochemically 
active form. This yeast grows to very high densities in fermenter or flask cultures providing ample 
cellular material. However, the modest expression level of the human variant of this integral 
membrane protein still presented undesirably low yields in protein production in several previous 
works 75, 76. 
Bai et al. 82 suggested that codon usage bias may be one of the factors leading to inefficient 




adjusted sequence of mouse P-gp-encoding mdr3 gene resulted in a significant increase in P-gp 
expression. We hypothesize that a gene for human P-gp optimized for translation in Pichia pastoris 
would allow higher protein expression levels than observed using human DNA sequences for P-
gp. 
 
3.1.2 The PichiaPinkTM system:  
To overcome the disadvantages of low protein expression, a new P. pastoris system called 
PichiaPinkTM has been reported 94, 98, 99. This new system based on Pichia pastoris is suggested for 
high-level (g/liter) and large scale (1000+ liter) production of recombinant proteins 98 and supplies 
a new and efficient way to screen high-expression transformants 94, 98.  
The strains in the PichiaPinkTM system contain a full deletion of the ADE2 gene 94, 98, 107-
109 and are unable to grow in the absence of adenine (ADE2 auxotroph). The ADE2 gene encodes 
phosphoribosylaminoimidazole carboxylase, an enzyme that catalyzes the sixth step in the de novo 
biosynthesis of purine nucleotides 94, 98, 107-110. The host PichiaPinkTM strain is an ade2 knockout 
and is autotrophic for adenine. Insufficient transformation or integration of ADE2 encoding vector 
DNA then results in the accumulation of red-colored purine precursors in the vacuoles of the cells. 
Colonies with low levels of the integrated vector will be pink or red, while colonies with higher 
levels of integration of ADE2 will appear white 110, 111. The available PichiaPinkTM plasmids 
include the wildtype ADE2 gene for complementation, ensuring high stability of transformants 
after chromosomal integration and easy identification when selected in minimal media lacking 
adenine. They also contain convenient restriction sites for cloning of the gene of interest under the 




this system also ensures clonal stability during scale-up for protein expression when rich media 
are employed. 
To reduce the impact of proteases and the need for heavy protease inhibitor use, three 
protease knockout strains are available for use along with a protease normal Pichia strain. These 
strains include a pep4 knockout, which prevents it from synthesizing protease A, a prb1 knockout, 
which prevents it from synthesizing protease B, and a pep4 prb1 double knockout 98, 112. These 
strains should allow for screening of transformant-integrant with minimal P-gp protein degradation 
and may help conserve expensive protease inhibitors that have been normally required. 
The system includes a choice between two cloning vectors with different ADE2 promoter 
strengths, pPink-HC and pPink-LC (high and low-copy number expression). The promoter 
deletion in the HC vector decreases the expression of the ADE2 gene product, necessitating 
additional copies for adequate complementation and loss of the red phenotype.  Again, the color 
of the colonies will indicate relative expression levels of the protein of interest since the colony 
color depends on the copy number of the integrated plasmid 98. 
Furthermore, in the expression plasmids of this system, only the AOX1 promoter is used to 
drive expression of the gene of interest encoding the desired heterologous protein, avoiding the 
adverse influence of the AOX2 promoter observed in some earlier vectors 98.  
 With all these combined advantageous features of the PichiaPinkTM vectors (figure 3.1), 






Figure 3 1: PichiaPink cloning vectors pPink vectors. 
pPink-LC and pPink-HC vectors, including the ADE2 gene for complementation, AOX1 promoter 
(AOX1p), and the restriction endonucleases sites for EcoRI and KpnI in their multiple cloning 
sites98. 
 
3.1.3 The Pichia pastoris GS115 strain 
GS115 is a mutant strain of P. pastoris that contains a defective histidinol dehydrogenase 
(his4) that prevents histidine synthesis113. GS115 His- cannot grow on a minimal medium unless 
it is supplemented with histidine. A plasmid vector containing the wild-type HIS4 gene would 





Figure 3 2: Restriction map of the plasmid pHIL-D2 
 
In this system, depending on the plasmid of choice, there is a different integration process99. 
Transformation of the GS115 P. pastoris cells with linearized pHIL-D2 (figure 3.2) favors gene 
replacement from a double crossover event between the AOX1 promoter and the 3’ AOX1 regions 
of the vector and genome (figure 3.3), causing a complete removal of the AOX1 coding region. 
The loss of the AOX1 gene results in the Muts (Methanol utilization slow) strain that exhibits poor 
growth on a minimal medium containing methanol as the sole carbon source. With pHIL 
containing the wild-type HIS4, the resulting phenotype of successful recombinants will be His+ 
and Muts. With two different markers (His and Mut), the chances of identifying and select 






Figure 3 3: Gene replacement at AOX1 in GS115 – image reproduced by the manual (Invitrogen) 
 
3.2 Results 
3.2.1 Cloning human P-gp into the PichiaPinkTM system 
Previous work has shown that codon optimization of MDR3 P-gp resulted in increased 
protein yield82. The new MDR1 clone was designed with optimized codon usage for translation in 
P. pastoris was commercially synthesized and cloned by using in-house programs at GenScript, 
Piscataway, NJ.  The codon optimization was assessed using the “Graphical Codon Usage 







Figure 3 4: Schematic view of the codon-optimized MDR1 gene, MDR1-subsites2.  
A Kozak sequence was incorporated on the 5’end of the reading frame, while EcoRI and KpnI 
restriction sites were incorporated at each end of the construct. Single unique sites for Pstl, Xmal, 
Apal, and SalI were incorporated, allowing cloning of subsections of the gene. The DNA was 
synthesized using standard Gibson assembly methods. 
 
The optimized MDR1 gene sequence that encodes for the human P-gp protein sequence 
(figure 3.4) was designed with a strong Kozak sequence on the 5’end of the reading frame, and 
EcoRI and KpnI restriction sites were incorporated at each end of the construct for force cloning 
into pUC57 (figure 3.5) and pPink vectors (figure 3.1). In addition, four internal unique restriction 
sites for Pstl, XmaI, Apal, and SalI were incorporated into the P-gp DNA sequence by silent 
mutations that together with unique 5’EcoRI and 3’KpnI sites allow the subcloning of 5 (five) 
approximately equal-sized subsections of the gene for facile troubleshooting and mutagenesis. 
After these design elements were incorporated in the sequence, the DNA was synthesized by 
GenScript using standard Gibson assembly methods114. pUC57 was used as a cloning vector for 
this initial DNA construct (figure 3.5, left panel). Transformation into CopyCutterTM EPI400TM 
Electrocompetent E.coli (EPICENTRE) 115 allowed replication of the multicopy pUC57–MDR1 





Figure 3 5:  pUC57 DNA plasmids 
pUC57 plasmid (2710 bps - GenScript) and pUC57-MDR1-subsites2 plasmid (6576 bps) 
 
The initial growth of the E. coli strain containing the pUC57-MDR1-subsites2 plasmid in 
attempts to isolate the multicopy plasmid failed (figure 3.6 b). Difficulties in the replication and 
maintenance of MDR1 gene sequences in E. coli, especially on high copy number plasmids, have 
been observed by us previously. The E. coli strain containing the pUC57-MDR1-subsites2 plasmid 
was allowed to grow, and the plasmid was prepared according to the ZymoTM Plasmid Miniprep 
protocol (Zymo Research).  These preparations were then digested with the restriction 
endonucleases EcoRI and KpnI. It was possible to see faint bands of our desired 3866 bps insert 
size (figure 3.6 c). Still, it was clear that it would not be possible to obtain the desired amount of 





Figure 3 6: pUC57-MDR1 subsites2 plasmids  
(a) Comparison of GeneRuler (GR) 1 Kb DNA ladder (ThermoFisher ScientificsTM) and 
Supercoiled (SC) DNA ladder (NEB). (b) Plasmid preparation after different induction growth 
conditions in EPI400 E. coli Electrocompetent strain. Lane 1: GeneRuler (GR) 1 Kb DNA ladder 
(ThermoFisher ScientificsTM); Lane 2: pUC57-MDR1-subsites2 plasmid after use induction 
solution; Lane 3: pUC57-MDR1-subsites2 plasmid IPTG induced; Lane 4 and 5: pUC57-MDR1-
subsites2 plasmid uninduced. (c) Restriction endonuclease digestions - EcoRI/KpnI – pUC57-
MDR1-subsites2. Lane 1: plasmid pUC57-MDR1-subsites2 uncut (6576 bps). The correct plasmid 
size is shown with a dashed arrow. See (a) for Supercoiled (SC)DNA ladder (NEB); Lane 2: 
pUC57-MDR1-subsites2 single cut KpnI; Lane 3: pUC57-MDR1-subsites2 double-cut 
EcoRI/KpnI top arrow presents the 3866 bps insert, bottom arrow presents the 2710 bps plasmid 
pUC57; Lane 4: GeneRuler (GR) 1 Kb  DNA ladder (ThermoFisher ScientificsTM). 
 
The MDR1-subsite2 DNA (3866 bps) was then amplified by polymerase chain reaction 
(PCR) using M13 universal primers (figure not shown) in attempts at salvaging the synthesized 
gene. In experiments aimed at cloning the insert DNA directly into pPink vectors, the PCR product 
of these reactions was digested with EcoRI and KpnI for insertion into the pPink plasmids. The 
vector DNA was 5’ dephosphorylated by Shrimp Alkaline Phosphatase (rSAP) (New England 
Biolabs). EcoRI/KpnI cut PCR fragment was then ligated into the pPink plasmid 
dephosphorylated, double-cut DNA before transformation into E. coli DH5α and NEB Stable 





Figure 3 7 – pPinkHC vector/MDR1-subsites 2 insert ligation attempts.  
(A) schematic representation of the ligation experiment attempts. (B) Ligation 5:1 PCR product 
using AOX1for and CYC1rev pPink primers and Hot Start Taq2X Master Mix (NEB).  
 
The first cloning attempt used a 3:1 insert/vector ratio and the quick ligation kit from New 
England Biolabs. After transformation into NEB® Stable competent E. coli high-efficiency cells, 
no ampicillin-resistant transformants were observed (figure 3.7 a, top). A second ligation attempt 
was made with a 3:1 insert/vector ratio, and the ligated product was then used to transform not 
only the Stable E. coli high-efficiency competent cells (NEB) but also NEB® 5-alpha Competent 
E. coli to test whether the previous ligation/transformation result was due a strain dependence 
issue. There was no growth of transformants on NEB® 5-alpha Competent E. coli plates except for 
the LB agar plate ‘cells only’ control showing there was good viability of the cells. There were 
few small colonies growing on NEB® Stable competent E. coli high-efficiency cells in the 
experimental plates (figure 3.7 a, middle). These colonies were inoculated in Luria-Bertani (LB) 
broth media with ampicillin for overnight cultures followed by plasmid preparations the next day 




preparations were size screened in a 0.6% agarose gel electrophoresis, and the plasmids presented 
a pattern similar to the one presented by the pPink vector-only control (figure not shown).   
A third attempt was made using a 5:1 insert/vector ratio, and the transformation was made 
again in NEB® Stable competent E. coli high-efficiency cells. PCR amplified the ligation mixture 
to assess whether the desired construct was present in the ligation using primers complementary 
to vector DNA that flanked the insert. A very faint band was observed on agarose gel after 
electrophoresis of the PCR samples (figure 3.7 b), suggesting that the desired ligation product was 
present. The yield of desired product was likely not sufficient to the success of the experiment, 
however, since most of the subsequently isolated transformed plasmids were again almost identical 
in size to the vector-only control, ~ 7,732 bps, instead of the 11,585-bps predicted for the 
successful vector insert (figure 3.8). In control experiments with dephosphorylated vector DNA 
subjected to ligation, no transformants were observed, suggesting that the dephosphorylation 






Figure 3 8: Plasmid prep from NEB® Stable competent E. coli high-efficiency cells /pPinkHC-
MDR1 or pPINKLC-MDR1.  
The top gels are pPinkLC-MDR1, and the bottom gels are pPinkHC-MDR1 (except on the bottom 
right pPinkLC-MDR1 #4.5. The first number indicates the colony's plate, and the second number 
shows the number of the colony picked.  
 
Additional transformation experiments were performed, and the plasmid preparations of 
pPinkHC-MDR1 show DNA rearrangements after transformation into the E. coli strain NEB 
StableTM (figure 3.8). Control vector pPinkHC only makes it clear that the plasmid size is almost 
identical to the vector only in most of the preps. λ DNA/HindIII Marker DNA ladder and 
Supercoiled DNA ladder on the left side. (Add expected size for the correct plasmid). 
The difficulties in obtaining the correct pPinkHC-MDR1 plasmid made us believe that the 
full MDR1-subsites2 DNA sequence could be potentially toxic. We then decided to start the 
subcloning of the MDR1-subsites2 DNA fragment to find a more stable way to combine the MDR1 





 As we did not know which fragment or combination of fragments could cause the 
rearrangements, each section was tested separately to investigate the problem.  
The gene sequence MDR1-subsites2 was designed to contain 4 internal unique restriction 
sites, allowing 5 subsections of MDR1. The first step was to cut each subsection with their 
correspondent enzyme restriction to separate the sections and then clone each one into a puc57 
clone vector with transformation into E. coli strain. This way, we could study each sequence and 
fix it, if necessary, before combining all subsections to continue the attempts to clone the whole 
insert.  
Using the MDR1-subsite2 DNA (3866 bps) that was amplified by PCR earlier, the 
restrictions enzyme applied to separate the subsections were: EcoRI-HF (NEB)/PstI (Fermentas) 
for the subsection A (~773 bps), PstI/XmaI (NEB) for the subsection B (~938 bps), XmaI/ApaI 
(NEB) for the subsection C (~814 bps), ApaI/SalI (NEB) for the subsection D (~789 bps) and SalI-
KpnI-HF (NEB) for the subsection E (~640 bps). All subsections were sequence-verified before 
proceeding with the next step. Vector pUC57 was treated with the same enzyme restriction for 
each subsection to perform vector/subsection ligation reaction (NEB Quick T4 Ligation kit). 
Before the ligation reaction, the plasmid vector was also dephosphorylated to prevent self-ligation.  
Ligated vector/MDR1 subsection plasmid was attempted to be transformed into different 
E. coli strains. Plasmids with the subsections A, C, D, and E were successfully transformed into 
the NEB DH5α E. coli strain (figure 3.9 b). In contrast, the plasmid containing subsection B could 
only be transformed into the SURE Supercompetent E. coli cells (Agilent technologies) (figure 3.9 
c). Sequences were again sent for verification since we needed to track for DNA sequence 




To reassemble the subsections, the attempt was to combine subsections A, B, and C first 
(MDR1 ABC), then subsections D and E (MDR1 DE). MDR1 ABC and MDR1 DE were ligated 
with the pUC57 vector separately and transformed into DH5α E. coli (Figures 3.9 d and 3.9 e).  
After successful transformation, a large growth and a larger scale plasmid preparation 
(ZymoPure midiprep protocol) were performed to obtain enough material for the next steps. The 
plasmids were then digested to isolate the MDR1 ABC and MDR1 DE fragments for the following 
ligation reaction.  
 
 
Figure 3 9: MDR1 Subcloning - pUC57-MDR1 subsections A-E and subsections assembly.  
(a) Comparison of GeneRuler (GR) 1 Kb DNA ladder (ThermoFisher ScientificsTM) and 
Supercoiled (SC) DNA ladder (NEB).  (b) Plasmid preparations of pUC57-MDR1 subsections A, 
C-E from NEB5-alpha High Competent cellsTM (undigested). Lane 1: GeneRuler (GR) 1 Kb, Lane 
2: pUC57 cloning vector; Lane 3: pUC57-MDR1-A (3350 bps); Lane 4: pUC57-MDR1-C (3517 
bps); Lane 5: pUC57-MDR1-D (3497 bps); Lanes 6: pUC57-MDR1-E (3306 bps), all plasmid 
preparations uncut. (c) Plasmid preparation pUC57-MDR1-B from SURE 2 Supercompetent 
cellTM Lane 1: GeneRuler (GR) 1 Kb; Lane 2: pUC57 cloning vector uncut; Lane 3: pUC57-
MDR1-B lower band (3638 bps). (d) Plasmid preparation of pUC57-MDR1-ABC. Lane 1: 
GeneRuler (GR) 1 Kb; Lane 2: pUC57 cloning vector uncut; Lanes 3: pUC57-MDR1-ABC. 
MDR1-ABC verified by sequencing. (e) Plasmid preparation of pUC57-MDR1-DE. Lane 1: 
GeneRuler (GR) 1 Kb; Lane 2: pUC57 cloning vector uncut; Lanes 3: pUC57-MDR1-DE. The 





 The ligation reaction was successful, and after transformation into SURE 2 
Supercompetent cellsTM (figure 3.10 b, lane 6), the PCR product from pPinkHC-MDR1 (figure 
3.10 c) was sent to sequencing, where we were able to verify the full MDR1 sequence. The 
plasmid was then linearized by SpeI single digestion (figure 3.10 d) for electroporation into all 
four PichiaPinkTM strains. The linearized pPinkHC-MDR1 vector (figure 3.10 d) was desalted by 
ethanol precipitation and electroporated into electrocompetent PichiaPink cells.  
 
 
Figure 3 10: Plasmid preparations of pPinkHC-MDR1 ABC+DE from SURE 2 Supercompetent 
cellsTM for electroporation into Pichia pastoris.  
(a) Left: λ DNA/HindIII Marker DNA ladder; right: comparison of GeneRuler (GR) 1 Kb DNA 
ladder (ThermoFisher ScientificsTM) and Supercoiled (SC) DNA ladder (NEB). (b) Lane 1: λ 
DNA/HindIII markerTM; Lane 2: pPinkHC vector uncut; Lane 3-6: Uncut plasmids pPinkHC 
MDR1 A-E #1-4. Lane 6 sequence verified. (c) PCR product from pPinkHC-MDR1 – 
AOX1/CYC1 primers. Lane 1: GeneRulerTM 1 Kb DNA ladder, Lane 2: pcr product of pPink-
MDR1 ABC+DE (~3930 bps). (d) pPinkHC-MDR1 ABC+DE SpeI single digestion for 
electroporation in Pichia pastoris. Lane 1: λ DNA/HindIII markerTM; Lane 2: pPinkHC-MDR1 
3.10 SpeI cut (11516 bps); Lane 3: pPinkHC-MDR1 3.10 #1 uncut (11516 bps). 
 
Recombinants exhibiting His+, Muts phenotype were selected, and small-scale cultures were 
grown to confirm the correct DNA insert into the yeast genomic DNA. The cells were lysed, and 




successful integration of the MDR1 DNA sequence into the genomic DNA of the PichiaPinkTM 
strains (figure 3.11). 
 
 
Figure 3 11: PCR screening from PichiaPink strains MDR1 lysates.  
(A) Pichia 1 + MDR1: Lane 1: PCR reaction control C – plasmid pPinkHC-MDR1 was used as 
DNA template (PCR product ~4046 bps); Lane 2: 1Kb GeneRuler DNA ladder; Lane 3: PichiaPink 
strain 1 cells only + pPinkHC-MDR1 plasmid (+); Lane 4: PichiaPink strain 1 cells only (-); Lanes 
5-10: PichiaPink strain 1 cells + MDR1 colonies 1.1-1.6. (B) PichiaPink strain  2 + MDR1: Lane 
1: PCR reaction control C – plasmid pPinkHC-MDR1 was used as DNA template (PCR product 
~4046 bps); Lane 2: 1Kb GeneRuler DNA ladder; Lane 3: PichiaPink strain 2 cells only + 
pPinkHC-MDR1 plasmid (+); Lane 4: PichiaPink strain 2 cells only (-); Lanes 5-10: PichiaPink 
strain 2 cells + MDR1 colonies 2.1-2.6. (C) PichiaPink strain 3 + MDR1: Lane 1: PCR reaction 
control C – plasmid pPinkHC-MDR1 was used as DNA template (PCR product ~4046 bps); Lane 
2: 1Kb GeneRuler DNA ladder; Lane 3: PichiaPink strain 3 cells only + pPinkHC-MDR1 plasmid 
(+); Lane 4: PichiaPink strain 3 cells only (-); Lanes 5-10: PichiaPink strain 3 + MDR1 colonies 
3.1-3.6. (D) PichiaPink strain 4 + MDR1: Lane 1: PCR reaction control C – plasmid pPinkHC-
MDR1 was used as DNA template (PCR product ~4046 bps); Lane 2: 1Kb GeneRuler DNA 
ladder; Lanes 3-8: PichiaPink strain 4 cells + MDR1 colonies 4.1-4.6; Lane 9: PichiaPink strain 4 
cells only + pPinkHC-MDR1 plasmid (+); Lane 10: PichiaPink strain 4 cells only (-). 
 
To ensure that MDR1 DNA was correctly integrated into the Pichia genome, genomic 




MDR1 internal primers (MDR1_int1for/MDR1_int6rev). We also performed single digestions of 
the PCR products with the internal XmaI restriction site (figure 3.12). All tests confirmed that the 
correct MDR1 DNA sequence was successfully integrated into the PichiaPinkTM strains. 
 
 
Figure 3 12: Integration genomic DNA tests 
(A) GeneRuler (GR) 1 Kb DNA ladder (ThermoFisher ScientificsTM); (B) left: MDR1 PCR 
product cut by XmaI enzymatic digestion. Right: PCR products from genomic DNA with 
PichiaPinkTM and MDR1 primers. 
 
A single colony from a plate of transformants from each PichiaPinkTM strain was selected for 
small-scale cultures for P-gp expression verification. The cells were first inoculated in glycerol-
based media for 24 hours, and then the medium was switched to a methanol-based medium for 72 
hours to allow protein expression. Crude membrane extracts were prepared (mini microsome 
preparations described in the methods), and P-gp expression was thought to be achieved through 





Figure 3 13: MDR1 expression after DNA integration into the yeast genome. 
(A) Pilot expression – top: PAGE Coomassie blue staining; bottom: Western Blot: C219 anti-P-
gp antibody. Colony code and strain are listed on the top of each well. (B) Comparison pilot sample 
1.2 and the MDR1 cysteine-less control – top PAGE Coomassie blue staining; bottom: western 
blot using C219 anti-P-gp antibody.  
 
 
 Previous work using the human cysteine-less P-gp (MDR1 Cl – chapter 2) an aliquot of 
one of the past preparation of MDR1 Cl was used as control on the immunobloting assay variant 
with the new cloned human P-gp wild-type (figure 3.13). The signal from MDR1 Cl was observed 
to appear slightly higher in the gel than the pilot culture 1.2 (PichiaPink-MDR1 strain 1); however, 
the difference could be due to differences in the protein glycosylation. According to previous 
success using this antibody, we confirmed human P-gp (MDR1) expression in the small-scale 
cultures (figure 3.13 A, bottom panel). Larger cultures were then prepared as referred to in the 
Methods and Materials section. Aliquots were taken over time to track P-gp expression levels 




harvested, mini microsome preparations were made on the aliquots for expression analysis, and 
microsome preparations were made from the larger cultures to break the cells and access the 
membranes. 
 To check the quality of the microsome preparations, aliquots of each fraction were taken 
for analysis (figure 3.14).  
 
 
Figure 3 14: MDR1 microsome prep analysis. 
Lane 1: Spectra ladder 10-260 kDa; Lane 2: final microsome pellet; Lane 3: supernatant 3; Lane 
4: supernatant 2; Lane 5: pellet 1 (unbroken cells) 
 
 
 From immunoblotting analysis, we observed that the fractions of supernatants 2 and 3, after 
ultracentrifugation at 45,000 rpm, still presented P-gp, while the last microsomal fraction showed 
almost no P-gp. Changes in the glycerol content from the buffer used on these fractions were 




 Next, we wanted to test if any cross-reactivity of the antibody would give us a false positive 
on the P-gp expression on our pilot cultures. For this, we used a blot from a culture that expresses 
BCRP (Breast Cancer Resistance Protein) but not P-gp (figure 3.15). 
 
 
Figure 3 15: Antibody cross-reactivity test 
Left panel: immunoblot for BCRP expression on PichiaPink strains using B1- anti ABCG2 
(BCRP). Right panel: the same immunoblot using now C219 anti-P-gp antibodies.  
 
 Cross-reactivity of C219 antibody on PichiaPinkTM membrane was detected on the BCRP 
immunoblotting. The same test was repeated using PichiaPinkTM cells only control 
(electroporated without plasmid), resulting in the same signal around 130 kDa (data not shown). 
The data showed we did not have P-gp expression initially, even though the correct MDR1 DNA 
sequence was integrated into the PichiaPinkTM genome. 
  
3.2.2 MDR1 cloning into GS115 Pichia pastoris strain 
The difficulties of expression of MDR1 in Pichia PinkTM made us try to use the optimized 




Our lab only had the pHIL-E556C-MDR1 plasmid containing another recombinant P-gp 
(gifted by Dr. Alan E. Senior – University of Rochester Medical Center, Rochester, New York). 
The solution was to remove the original P-gp insert from pHIL to insert back our new version. 
To achieve this, we used the restriction sites for SacII and XhoI on pHIL-E556C-MDR1(figure 
3.16 c) to remove the E556C-MDR1 sequence to obtain the pHIL cloning vector. We developed 
adapter primers mdr1-pink-to-hil for/mdr1-pink-to-hil-rev to include both restriction sites before 
and after the MDR1 sequence (figure 3.16 a and b) from the pPinkHC-MDR1 plasmid. 
 
 
Figure 3 16: insert vector preparation for cloning in Pichia GS115. 
(A) Sequence of the adapter primers mdr1-pink-to-hil for/rev; (B) MDR1 insert removed from 
PichiaPink-MDR1 plasmid digested with SacII and Xhol; (C) pHIL-E556C plasmid before MDR1 
E556C sequence removal – circled in red SacII and Xhol restriction sites. 
 
The codon-optimized MDR1 gene was removed from the PichiaPink-MDR1 plasmid to be 




performed to confirm if the correct MDR1 sequence was removed from the original vector before 
insertion into the host vector, pHIL (figure 3.17). 
 
 
Figure 3 17: MDR1 pink-to-hil - Screening steps to remove MDR1 sequence from pPinkHC-
MDR1 plasmid to insert into the pHIL cloning vector.   
(A) Lane 1: pHIL-E566c plasmid uncut; Lane 2 (1 kb GeneRuler); Lane 3 pHIL-MDR1 final 
plasmid. (B) PCR products from plasmid pHIL-MDR1 using pHIL primers 1 and 2, and MDR1 
internal primer #5 and pHIL reverse primers. (C) pHIL-MDR1 restriction enzyme digestion using 
MDR1 internal sites: EcoRI, ApaI 
 
Both insert MDR1, and the plasmid pHIL-E556C were double digested with the restriction 
enzymes, SacII and XhoI to generate complementary ends. After removing the MDR1 DNA 
sequence from the PichiaPinkTM plasmid, the insert was ligated into a pHIL cloning vector and 
transformed into Sure 2 competent cellsTM (Agilent/Stratagene). The plasmid was then linearized 
with NotI (figure 3.18) and desalted before integration into Pichia GS115 cells. Integration was 






Figure 3 18: Plasmid preparation for electroporation in Pichia pastoris GS115 by restriction 
enzyme digestion. 
(A) NotI digestion 1 hour – Lane 1: λ DNA/ HindIII marker; Lane 2: MAXIprep pHIL-MDR1 
uncut (12113    bps); Lane 3: NotI digestion pHIL-MDR1 (9233 bps) and smaller fragment (2880 
bps); Lane 4 Gene ruler 1kb DNA ladder.  (B) NotI digestion 3 hours – Lane 1: λ DNA/ HindIII 
marker; Lane 2: NotI digestion pHIL-MDR1 (9233 bps) and smaller fragment (2880 bps). 
 
After electroporation, the cells were incubated in 1M sorbitol at 28oC for 2 hours to recover. 
They were plated on Minimal Dextrose (MD) and Minimal Methanol (MM) plates supplemented 
with 1M sorbitol (MDS).  After 5 days of incubation at 28oC, the resulting colonies were re-
streaked on fresh MD/MM plates to confirm the His+ phenotype. Control strains with cells 
electroporated with no DNA insert were also streaked to differentiate between the Mut+ and Muts 
phenotypes. The presence of the MDR1 gene was confirmed through PCR of cellular lysates 
(figure 3.19 a).  
Recombinants exhibiting the His+, Muts phenotype were selected, and small-scale cultures 
were grown to test for P-gp expression. Integration of the MDR1 gene was confirmed in 
transformed yeast strains, and its sequence was verified. Glycerol stocks were made from this 
colony. 0.6% agarose gel of PCR products of genomic DNA from transformed Pichia GS115. 
MDR1 internal primers were used to probe genomic DNA for the presence of the predicted 2842 





Figure 3 19: MDR1 DNA and expression screening in Pichia pastoris GS115.  
(A) MDR1 DNA sequence integration. Lane 1: PCR product of pHIL-MDR1 plasmid control; 
Lane 2, GeneRulerTM 1 Kb DNA ladder; Lane 3, GS115 untransformed cells spiked with pHIL-
MDR1 plasmid control; Lane 4, untransformed GS115 cells, negative control; Lane 5 GS115-
MDR1 transformant sample #22. (B) Immunoblot for P-gp expression from small-scale growth 
with or without the presence of 500 nM Tariquidar. Duplicate blot – left: C219 anti-P-gp antibody, 
right: anti-HIS antibody. Lane 1: MDR1 #22; Lane 2: MDR1 #22 + 500 nM Tariquidar (TRQ); 
Lane 3: MDR1 #25; Lane 4: MDR1 #25 + 500 nM TRQ; Lane 5: Spectra Protein ladder 10-260 
kDa; Lane 6: MDR1 Cl mini microsome control. 
 
A small-scale growth was performed using glycerol stocks, and the cells were lysed with a 
mini microsome preparation.  The same pattern of expression observed on PichiaPink-MDR1 was 
observed here with cross-reactivity of the C219 anti-P-gp antibody lower than the expected P-gp 
size compared with the MDR1 CL control (figure 3.19 b). P-gp expression was not confirmed 
through immunoblot analysis using the monoclonal antibody C219 – mouse anti-P-gp (Enzo Life 
Sciences).  
 
3.3 Methods and materials 
3.3.1 E. coli strains: 





Table 3 1: Details of the E. coli strains used in the experiments.  
Strain Genotype 
CopyCutterTM EPI400TM 
Electrocompetent E. coli 
(EPICENTRE) 
F– mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 ∆lacX74 
recA1 endA1 araD139 ∆(ara, leu)7697 galU galK λ– rpsL nupG 
tonA ∆pcnB dhfr 
NEB® Stable competent E. 
coli (High Efficiency) 
F’ proA+B+ lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) ∆(ara-leu) 7697 
araD139 fhuA ∆lacX74 galK16 galE15 e14-  Φ80dlacZ∆M15 
recA1 relA1 endA1 nupG rpsL (StrR) rph spoT1 ∆(mrr-hsdRMS-
mcrBC) 
NEB® 5-alpha Competent 
E. coli (High Efficiency)  
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
SURE 2 Supercompetent 
cells (Agilent) 
e14-(McrA-) Δ(mcrCB-hsdSMR-mrr)171 endA1 gyrA96 thi-1 
supE44 relA1 lac recB recJ sbcC umuC::Tn5 (Kanr) uvrC [F´ 
proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
 
3.3.2 Agarose gel electrophoresis:  
 0.6% agarose gels with 4.5 x 10-5% ethidium bromide were used and DNA visualization 
was made under UV light.  
3.3.3 Polymerase chain reaction (PCR):  
The Taq DNA polymerase from New England Biolabs was gifted by Ms. Lynn McBee, 
NEB. PCR reactions were performed as described in the manufacturer protocol. In short, Taq DNA 




µM Reverse Primer, template DNA, and nuclease-free water. 30-35 cycles were used on different 
reactions and templates. Annealing temperatures were defined according to the primer set and 
calculated by the NEB Tm calculator (http://tmcalculator.neb.com). The reactions ran on the MJ 
Research PTC-200 Peltier Thermal Cycler.  
3.3.4 Restriction enzyme digestions:  
Reaction digestions were performed as directed in the manufacturer protocol (New 
England Biolabs®). In short, 1 µg of DNA was incubated in 50 µL total volume with appropriate 
enzyme units as listed in the protocol received with the enzyme. Reactions were incubated at 37oC 
for 1-2 hours.  
3.3.5 Vector Dephosphorylation: 
New England Biolabs® Shrimp Alkaline Phosphatase (rSAP) dephosphorylated kit was 
gifted by Lynn McBee. The dephosphorylation was performed as described in the protocol. The 
linearized vector DNA, 10X CutSmart Buffer, 1 uni of rSAP, and deionized water up to 20 µL 
were added. The mixture was incubated at 37oC for 30 min. The reaction was then heat-inactivated 
at 65oC for 5 minutes. 
3.3.6 Ligation:  
The quick ligation kit from New England Biolabs® was kindly gifted by Lynn McBee. The 
vector DNA was mixed with insert DNA at different molar ratios (1:1 up to 5:1), 2 µL of 2X Quick 
Ligase Reaction Buffer added, water to a total volume of 19 µL, and 1µL of Quick Ligase. The 
solution was mixed, centrifuged, and incubated at 25oC for 5 min. After a brief incubation on ice, 
1-5 µL of this reaction was used in transformation experiments. NEBioCalculator was used to 




3.3.7 Bacterial transformation 
Competent cells were thawed on ice for 10 min. 1-5 µL of a ligation mixture was added to 
50 µL of cells, and the tube was flicked to mix and incubated on ice for 30 min. A heat shock was 
performed for 30 seconds in a water bath at 42oC before incubation on ice for 5 min. Then 950 µL 
of SOC medium (0.5 % Yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, 20 mM glucose) was added to the tube and incubated rotating or shaking for 60 
min at 37oC. The tube was mixed and plated on LB plates with ampicillin. Plates were incubated 
overnight at 37oC.  
3.3.8 Mini plasmid preparations: 
Zippy Plasmid Miniprep kits were obtained from Zymo Research, Inc. The provided 
protocol was followed. Pelleted culture cells were added to 600 µL of deionized H2O and placed 
in a 1.5 ml microfuge tube. 100 µL of 7x Lysis buffer was added, and the tube was inverted six 
times. 350 µL of 4oC Neutralization Buffer was added immediately after, and the tube inverted 
until the solution is all yellow and a precipitant is formed. The sample was centrifuged at 14,000 
x g in a tabletop MR22 microfuge for 4 min. The supernatant was poured into a Zymo-Spin 
column, placed in a collection tube, and centrifuged at the same speed for 15 seconds. The liquid 
in the collection tube was discarded, and 200 ul of Endo-Wash Buffer was added to the column 
and centrifuged for 30 seconds. 400 µL of Zippy Wash Buffer was added to the column and 
centrifuged for 30 seconds. The column was then transferred to a new microfuge tube, and 30 µL 
of deionized H2O was added to the column and incubated at room temperature for 1 min. The DNA 




3.3.9 Midi plasmid preparations: 
ZymoPURETM Plasmid Midiprep kits were obtained from Zymo Research, Inc, and the 
provided protocol was followed. Bacterial cells suspension was resuspended in ZymoPURE P1 on 
a 50 mL conical tube (red solution). The ZymoPURE P2 solution was added to the mixture and 
turned the solution dark purple. Indicating bacterial lysis was completed. ZymoPure P3 solution 
was added to the mixture, and the solution turned yellow, indicating neutralization was complete. 
The neutralized lysate was loaded into the ZymoPURE syringe filter and clarified into a new 50 
mL conical tube. ZymoPure Binding Buffer was added to the cleared lysate and mixed. The 
mixture was then loaded into the Zymo-Spin III-P Column, and a vacuum manifold was used to 
clear and wash the column. Pure DNA was eluted from the Zymo-Spin III-P column using the 
MR22 microfuge. 
3.3.10 DNA purification:  
DNA clean & concentratorTM-5 (Zymo Research) was used to purify and concentrate up to 
5 µg of DNA using the protocol provided. DNA Binding Buffer was added to the DNA sample in 
a 2:1 ratio for plasmid DNA or a 5:1 ratio for PCR products. The mixture was transferred to a 
Zymo-SpinTM Column in a collection tube and centrifuged at 14,000 x g in the MR22 microfuge 
for 30 seconds. 200 µL of DNA Wash Buffer was added to the column, and the centrifugation step 
was repeated. The wash was also repeated. 6-10 µL deionized water was added to the column and 
incubated at room temperature for 1 min. The column was placed in a new 1.5 ml microfuge tube 
and centrifuged for 30 seconds at 14,000 x g to elute the DNA 
3.3.11 DNA sequencing: 
After purified, the DNA was sent to Lone Star Labs, Inc. in Houston, TX, for standard 




sequence using the Basic Local Alignment Search Tool (BLAST) for nucleotides available from 
the NIH (https://blast.ncbi.nlm.nih.gov/Blast.cgi) 
3.3.12 Preparing electrocompetent Pichia pastoris cells:  
Strains 1, 2, 3, and 4 of PichiaPink, were streaked onto YPD plates (1% yeast extract, 2% 
bacto peptone, 2% dextrose, 1.5% agar) and incubated 28oC for up to 5 days. A single colony of 
each was used to inoculate 10 ml YPD media to grow overnight at 28oC, shaking at 250 rpm. This 
initial culture was used to inoculate 100 ml YPD media to a starting O.D. at 600 nm of ~0.2. This 
culture was grown until it reached an O.D. at 600 nm between 1,2 and 1.5 (between 12.-16 hours). 
The cells were harvested by centrifugation at 1,500 x g for 10 min at 4oC and resuspended in 250 
ml of ice-cold sterile water. The cells were pelleted again, and the cells were resuspended in 10 ml 
of ice bold 1 M Sorbitol. The centrifugation step was repeated, and the pellet was resuspended in 
300 µL of ice-cold 1 M Sorbitol to a final volume of about 500 µL. The cells were kept on ice until 
electroporation. 
3.3.13 Integration of the MDR1 gene into PichiaPink/GS115 cells by electroporation:   
100 µL of electrocompetent Pichia pastoris cells were added to a 0.2 cm cuvette (BioRad), 
and 15 µg of linearized DNA was added in a volume of less than 25 µL. The cells and DNA were 
incubated on ice for 5 min. Electroporation with 25 µF capacitance and 1.5 kV was performed 
with a time constant between 4.68 and 4.8 msec on a BioRad Gene Pulser II. After that, 1 ml of 
ice-cold YPDS media (YPD media + 1M Sorbitol) was added to the cuvette and mixed carefully 
by pipetting. The cuvette was then incubated for 2 hours at 28oC without shaking. The samples 
were then plated on PAD selection plates (PichiaPink cells) or MD/MM plates (GS115 cells) with 




3.3.14  Selection plates: 
- PAD selection plates: 13.4g/L Yeast Nitrogenous Base (YNB); 0.05 g/L Biotin; 20 g/L 
Dextrose; 50 mg/L L-Arg HCl; 80 mg/L L-Asp acid; 20 mg/L L-His HCl; 50 mg/L L-
Iso; 100 mg/L L-Leu; 50 mg/L L-Lys HCl ; 20 mg/L L-Met; 50 mg/L L-Phe; 100 mg/L 
L-Thr; 50 mg/L L-Try; 50 mg/L L-Tyr; 20 mg/L Uracil; 140 mg/L L-Val; 20 g/L Agar 
- MD plates: 1.34% YNB; 4x10-5% Biotin; 2% Dextrose; 5% Agar (w/v) 
- MM plates: 1.34% YNB; 4x10-5% Biotin; 2%; 1% Methanol; 5% Agar (w/v) 
3.3.15 Genomic DNA extraction:  
Transformants colonies were inoculated in a 2 ml YPD medium, and the cultures were set at 28oC, 
275 rpm for 24 hours on an incubator. After checking the successful growth in the cultures, each 
one was transferred to a 2 ml centrifuge tube and centrifuged to 14,000 x g for 1 min (Beckman 
22R Microfuge) to pellet the cells. The supernatant was discarded, and the cell lysis was made 
according to the protocol described in 116. Briefly, the pellets were resuspended in 300 µl of 
breaking buffer (200 mM Lithium Acetate; 1% SDS), and the samples were incubated for 10 min 
at 70oC. Regular ethanol precipitation protocol was followed: 1 ml 96-100% ethanol was added 
for DNA precipitation, the samples were then centrifuged at 14,000 x g for 3 min. Pellet was 
washed with 1.5 ml of 70% ethanol. The ethanol was dry using the Beckman tabletop vacufuge at 
1.400 x g for 30 min. The pellet was resuspended in TE buffer, and the samples were centrifuged 
again at 14,000 x g for 3 min. 1µl of the supernatant was used for PCR reaction. 
3.3.16 Growth of Pichia pastoris GS115 strain 
Cells were grown using the methods previously described in 70, 75, 76, 86. In short, A single 
colony from a Minimal Dextrose (MD) agar plate (1.34% Yeast Nitrogen Base (YNB), 4x10-5% 




medium (1.34% YNB, 1% glycerol, 4x10-5% Biotin) and incubated at 28oC with shaking to OD600 
of ~2.0 (18h). After 16-18 hours, this 10 ml was added to 1 liter of MG medium in a 2-liter 
Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was continued (~18h), then 
the cultures were centrifuged in sterile bottles (4000 rpm for 20 min at 23oC). Protein production 
was induced by switching the carbon source of the medium from glycerol to methanol. The cells 
pellets were resuspended in 1 liter of Minimal Methanol (MM) medium (1.34% YNB, 4x10-5% 
Biotin, 0,5% v/v methanol) in 2-liter Fernbach flasks covered with cheesecloth. Incubation 
continued for 72h with the addition of methanol (1% v/v) at 24 and 48 hours.  The pH correction 
was adjusted to ~6.0 at these times. Cells were finally collected by centrifugation at 4000 rpm for 
10 min at 4oC and resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3 M Tris-
HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at a 
concentration of 1 g wet cells/ml buffer. The cells were stored at -80oC. 
3.3.17 Growth of P. pastoris PichiaPinkTM:  
Cells were grown using the methods previously described in Invitrogen for PichiaPinkTM 
70, 75, 76, 86. In short, A single colony from a YPD agar plate (1.34% Yeast Nitrogen Base (YNB), 
4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 ml of liquid Enriched Minimal 
Glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 1% glycerol, 
4x10-5% Biotin, 100mM Potassium Phosphate) and incubated at 28oC with shaking to OD600 of 
~2.0 (18h). After 16-18 hours, this 10 ml was added to 1 liter of BMGY medium in a 2-liter 
Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was continued (~24h), then 
the cultures were centrifuged in sterile bottles (6000 rpm for 7 min at 23oC). Protein production 
was induced by switching the carbon source of the medium from glycerol to methanol. The cells 




extract, 10% Bacto Peptone, 1.34% YNB, 4x10-5% Biotin, 0,5% v/v methanol, 100mM Potassium 
Phosphate) in 2-liter Fernbach flasks covered with cheesecloth. Incubation continued for 72h with 
the addition of methanol (1% v/v) at 24 and 48 hours.  The pH correction was adjusted to ~6.0 if 
needed. Cells were finally collected by centrifugation at 6000 rpm for 7 min at 4oC and 
resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3 M Tris-HCl, pH 7.4, 1 mM 
EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at a concentration of 1 g wet 
cells/ml buffer. The cells were stored at -80oC.  
3.3.18 Mini microsome preparations from small scale yeast cells growth: 
Small scale growth of yeast follows the same procedures as the large scale but with smaller 
volumes (10 ml). After the growth, the cells were pelleted by centrifugation (4,000 x g, for 10 min 
at 4oC). Cell pellets were then resuspended in 500 µL-1 ml A1 buffer (30% v/v glycerol, 50mM 
Tris-HCl, pH 8, 125mM NaCl, 10mM imidazole) supplemented with protease inhibitors (2 µg/ml 
pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml PMSF and 10 µl/ml DTT).  The 
suspension and 1 ml of 0.5 mm glass beads (BioSpec) were added in a 2 ml cryovial tube, filled to 
the top with buffer A1. The tube was subjected to 5-7 cycles of shaking on a mini bead beater 
(BeadbugTM, Benchmark Scientific) to break the cells. The supernatant was then moved to a new 
2 ml microfuge tube, and the beads were rinsed with 1 ml A1 supplemented with protease 
inhibitors. The tubes were centrifuged at 14,000 x g for 30 min at 4oC. The supernatant was 
collected into 15 ml polycarbonate tubes and subjected to another centrifugation at 45,000 rpm for 
45 min at 4oC in a Ti 70.1 rotor in a Beckman Coulter Optima XPN-80 or LE-80K Ultracentrifuges. 
The pellet was resuspended in 200 µL A1 with protease inhibitors referred above and stored at -




3.3.19 Microsome preparation from yeast cells:  
Microsomes were prepared essentially as described in 86, with the modifications made in 
70, 75, 76. Frozen cells were rapidly thawed by incubating bottles in a water bath set at 28-30oC for 
~10 min, swirling the bottle's content to equilibrate the temperature. All further steps were 
performed at 4oC or on ice. Protease inhibitors were added once the cell suspension was thawed 
as follows: 2 µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml PMSF, and 
10 µl/ml DTT. All the cells were transferred to a chilled bead beater apparatus that was filled to 
top with “buffer A1” (30% v/v glycerol, 50 mM Tris-HCl, pH 8, 125 mM NaCl, 10 mM imidazole) 
supplemented with DTT (10µl/mL). Cells were mechanically disrupted by using 0.5 mm glass 
beads in a bead-beater (BioSpec) for a total of 14 minutes. The bead-beater was attached to a 
jacketed chamber filled with an ice-salt mixture that helped maintain the lower temperature. Cell 
disruption was performed in 7 cycles of 2 minutes bead beating alternated with 6 minutes with the 
bead-beater “off” to allow cells to cool down. This method helped solve the problem of overheated 
samples due to the high heat output of the bead-beater motor. The homogenate was then 
centrifuged for 30 minutes at 10,000 rpm (at Beckman J21-M equipped with a JA-20 rotor), and 
the pellet was discarded. These steps removed unbroken cells, nuclei, and mitochondrial fractions. 
The supernatant was centrifuged at 45,000 rpm (at Beckman Optima LE-80K equipped with Ti70 
or Ti55.2) for 45 min at 4oC. After this ultracentrifugation, the supernatant contained cytoplasmic 
protein and was discarded. The resulting pellet containing the microsomes was resuspended in 
“wash buffer” (20% v/v glycerol, 50 mM Tris-Cl, pH 7.4 at 4oC, and protease inhibitors – 1 mM 
PMSF, 1 mM DTT, Pepstatin A, Leupeptin, and Chymostatin as above). The microsomes were 
recentrifuged at 45,000 rpm at Beckman Optima LE-80K equipped with Ti70 or Ti55.2) for 45 




paintbrush and then by 10 strokes by hand in a Potter-Elvehjem Teflon pestle homogenizer in 30 
ml of “buffer A1” plus protease inhibitors as before). The microsomes were then frozen at -80oC.  
3.3.20 Western Blot analysis:  
Polyacrylamide gels at 6.5%, with a ratio of polyacrylamide to bis-polyacrylamide of 29:1, 
were used. The gels were loaded with the samples (10-40 µg of protein) and ran for 1.5 h at 110 
V before transferring to PVDF membrane (blot) for 100 min at 110V. The blot was incubated in 
blocking buffer (TBS-t with 5% low fat dry milk) for 1 hour at room temperature or overnight at 
4oC. After the incubation, the buffer was discarded, and the blot was washed 3 times with 5 min 
in TBS-t (12 mM Tris-Cl pH 7.5; 0.5 M NaCl; 0.05% v/v Tween-20). Following the washes, the 
blot was incubated in 1:1000 dilution in primary monoclonal antibody C219 – mouse anti-P-gp 
(Enzo) for 1 hour at room temperature or overnight at 4oC in a rocking platform. Another set of 3 
washes were applied to the blot. An incubation in 1:10,000 dilution secondary antibody goat anti-
mouse IgG-HRP was applied to the blot for one hour at room temperature in a rocking platform. 
The solution was discarded, and another set of washes were applied to the blot. For the 
chemiluminescent development, an equal amount of Luminol Enhancer Buffer (Detection 
Reagent 1) and the Peroxide Solution (Detection Reagent 2) (ThermoScientific) were mixed and 
pipetted onto the membrane and allowed to incubate at room temperature for at least 1 min before 
the development with chemiluminescent settings on a BioRad Chemidoc MP Imaging System.  
3.4 Discussion 
Several studies 82, 86 as well as our lab have reported on the expression of P-gp in the yeast 
Pichia pastoris and purified the protein in what was assumed to be a fully biologically active form. 
P. pastoris yeast grows to very high densities in fermenter cultures providing ample source 




lab.  The low protein yield during purification made it undesirable for further experimentation. Bai 
et al. 82 suggested that codon usage bias may be one of the factors leading to inefficient translation 
in Pichia, thereby limiting protein production.  A codon usage adjusted sequence of mouse P-gp-
encoding mdr3 gene resulted in a significant increase in P-gp expression 82. We hypothesized that 
a gene for human P-gp that has been optimized for translation in Pichia pastoris might allow higher 
levels of protein expression than observed using human DNA sequences for P-gp. 
The PichiaPinkTM system was also a promising approach to obtaining higher protein yield 
besides the advantages provided by strains 1, 2, and 3 with knock-out of proteases, which would 
make the purification process cheaper.  
A new gene that encodes the human MDR1 P-gp was created that was optimized for 
translation in Pichia pastoris. The DNA was commercially obtained and cloned into the pUC57 
cloning vector and transformed in the CopyCutterTM EPI400TM Electrocompetent E. coli strain 
115. The DNA also included unique internal restriction sites for subcloning so that individual 
sections of the MDR1 gene could be subcloned.  
We observed difficulties in replication and maintenance of the MDR1 gene sequences in 
E. coli strains. The great instability of the MDR1 gene made it hard to replicate DNA in E. coli 
strains, and the desired amount of MDR1 insert was only achieved by PCR. Several attempts to 
ligate the PCR product of MDR1-subsites2 insert into PichiaPinkTM high expression system 
vectors pPinkHC and pPinkLC were made using different insert/vector ratios into different E. coli 
strains and rearrangements were observed on most of our attempts. 
Subclones of the five MDR1 subsections – EcoRI-PstI (A), PstI-XmaI (B), XmaI-ApaI (C), 
ApaI-SalI (D), SalI-KnpI (E) - were made to identify which specific section of MDR1 DNA was 




were cloned without further problems on the E. coli strain DH5α. The section promoting 
rearrangements was subsection B that could only grow successfully using the SURE® 2 
Supercompetent cells (Agilent Technologies). According to the manufacturer, these cells lack 
components of important pathways that catalyze rearrangements and present deletions of 
nonstandard secondary and tertiary structures frequently found in eukaryotic DNA but impede 
the cloning of conventional E. coli strains. The cells were also endonuclease (endA) and 
recombination (recB recJ) deficient (Agilent). These features could present an important role in 
the successful cloning of subsection B in this specific strain.  
Once the subcloning was successfully made and all sequences were verified, we then 
proceeded with the reassembly of the sections. Surprisingly, the assembly of the subsections of 
MDR1 ABC and DE with the cloning vector pUC57 was easy to achieve, and the transformations 
in the E. coli strain DH5α were successful (figure 3.9 d and e).  
To prevent new rearrangements events, we decided to combine the MDR1 sections 
ABC+DE and ligate them with the PichiaPink plasmids and transform them into the SURE 2 
Supercompetent cells. The PCR product of the purified plasmid was finally sequence-verified, 
and the plasmid pPinkHC-MDR1 was then prepared for electroporation into the PichiaPinkTM 
strains. 
The transformation was successful, and the sequence of MDR1 was found on the genomic 
DNA of yeast.  
Small scale expression growth was made, and the use of C219 antibody against P-gp 
confirmed the presence of P-gp. Control MDR1-cysteine less presented a band slightly higher 




After confirming the expression, we decided to grow large-scale cultures (1L.) to perform 
a full protein purification preparation.  During the first step of breakage and formation of 
microsomes, all the fractions were saved and aliquoted for analysis. The first clue that something 
was not right was when the supernatant fractions from the ultracentrifugation - deemed to separate 
soluble to insoluble proteins – presented “expression” of P-gp. Changes in glycerol content of the 
medium were made with the same result.  
Several questions about why P-gp would appear in solution and not pelleted or if we ever 
had P-gp in the first place made us investigate the specificity of the C291 P-gp antibody. The 
C219 antibody anti-P-gp (Enzo) used in our experiments was largely used over the years to 
recognize different P-gp variants in our previous work from our lab. We found out that there was 
cross-reactivity of the P-gp in Pichia cells, and the band we see on the expression test was not P-
gp (figure 3.15).  
The PCR from the genomic DNA was tested after transformation and digestions using 
restriction enzymes to cut specifically at the MDR1 subsection’s restriction sites confirmed that 
the DNA sequence of MDR1 was indeed present on the yeast (figure 3.12). Still, for some reason, 
the protein was not being made.   
Since the PichiaPinkTM is a new system optimized for secreted protein, the problem could 
be on the membrane, not on the DNA. Multi copies of P-gp on membrane could not be supported 
by the cells.   
We still wished to take advantage of the codon-optimized MDR1 DNA sequence. We then 
target to clone it into the Pichia pastoris GS115 strain, the host of other P-gp strains we have 




We had no difficulties on extract the MDR1 sequence from the pPinkHC-MDR1. The 
cloning vector used on GS115 is pHIL. We needed to extract the pHIL cloning vector from the 
pHIL-E556C-MDR1 plasmid containing another recombinant P-gp. The MDR1 sequence present 
on the PichiaPink-MDR1 plasmid did not contain any specific sites similar to those found in the 
pHIL-E566C plasmid. On this plasmid, the restriction sites SacII and XhoI were found before and 
after the E566C-MDR1 sequence, respectively, making these two sites suitable to separate the 
cloning vector pHIL and the E566C-MDR1 insert. We then developed adapter primers mdr1-
pink-to-hil for/mdr1-pink-to-hil-rev to include both restriction sites before and after the MDR1 
sequence present on the PichiaPink-MDR1 plasmid. PCR successfully added both restriction sites 
on the MDR1 sequence target on the PichiaPink-MDR1 plasmid. Digestions on both fragments, 
plasmid, and optimized MDR1 insert, allowed later ligation, and the new plasmid pHIL-MDR1 
with the confirmed correct MDR1 sequence was easily linearized for integration into Pichia 
pastoris GS115 strain (figure 3.16).  
Screenings on the new Pichia GS115 were successful, and we were able to find 2 (two) 
transformants with the verified MDR1 sequence faster than the PichiaPinkTM screenings (figure 
3.17 a). Unfortunately, the outcome of the expression was not different from what was observed 
on the PichiaPinkTM strains. No expression was confirmed on both transformants. We should not 
have as many multi copies of P-gp on the membrane as the previous strain to justify the lack of 
expression. We hypothesize we would have a folding problem, and per Dr. David Clarke's 
suggestions, we wanted to add tariquidar during the growth of the yeast somehow to orient the 
folding of P-gp during its expression. The strategy also did not work, and we still did not confirm 




We could try obtaining mRNA expression by qPCR to track that translation from the DNA 
sequence and confirm the folding hypothesis. Still, after all the time and effort spent, we decided 
to stop it here and proceed in a different direction using the clone provided by Dr. Ina Urbatsch 
(Texas Tech University). 
 
  
CHAPTER 4                                                                                                                                     
P-GLYCOPROTEIN WILD-TYPE PURIFICATION – INITIAL HITS AND LIPID CONTENT 
EFFECT ON P-GP ACTIVITY 
 
4.1 Introduction 
A membrane protein-like P-gp has its activities affected by the molecular interactions 
between the protein and the surrounded lipid composition, such as hydrophobic effects, hydrogen 
bonding, or charge interactions. Lipid fluidity and membrane tension are also factors considered 
117.   
As described in chapter 1 and at 70, 80, the innovative approach from our group was to find 
a molecule/compound that would target the P-gp power source to prevent the ATP binding on the 
ATP binding domain – nucleotide-binding domain (NBD) – so the P-gp could not export the 
chemotherapy drugs across the membrane.  
From the high-throughput computational screens 72, 73 to identify the best predicted hit 
compounds for the in silico docking experiments -  as described on chapter 1,  – Brewer et al70, 
was able to test successfully the inhibitory effect of 4 (four) of those initial compounds (figure 4.1) 
on the ATPase hydrolysis activity by purified mouse P-gp while three of them – compounds SMU 
29[2-[(5-cyclopropyl-1H-1,2,4-triazol-3-yl)sulfanyl]-N-[2-phenyl-5-(2,4,5-
trimethylphenyl)pyrazol-3-yl]acetamide (ZINC 08767731, CID 17555821)], SMU 34 [2-[1-[4-(4-
methoxyphenyl)piperazin-1-yl]-1-oxobutan-2-yl]-4-methyl-[1]benzothiolo[2,3-d]pyridazin-1-




(3-phenylpropyl)piperidine-3-carboxylate (ZINC 15078148, ZINC 15078146, CID 26410703, 
CID 45252040)] -  showed the MDR-reversal in prostate cancer cell line 80,  and ovarian cancer 
cell line 1. More recently, computationally identified compounds were shown to reverse MDR in 
cancer cells and needed to be biochemically tested on isolated human P-gp (McCormick et al., 
unpublished) – see chapter 5. 
 
 
Figure 4. 1: The location of docked inhibitors in the human P-gp model from 70.  
The nucleotide-binding domains (NBD) are represented in a silver-gray cartoon showing where 
nucleotides (ATP and ADP) and compounds 19, 29, 34, and 45 were bound to this human P-gp 
model. 
 
For the initial biochemical analyses, mouse cysteine-less P-glycoprotein (mdr3-Cl) was 
used70. Even though it is closely related to the human MDR1 P-gp, it still presented some important 
differences that we wanted to explore.  After the initial difficulties on the purification of the human 
cysteine-less P-gp we had available in our lab and the failed attempts to clone the MDR1 gene into 
high expression in yeast (chapter 3), we decided to made use of another KM71H Pichia pastoris 
strain expressing human MDR1 wild -type that was kindly gifted by Dr. Ina Urbatsch (Texas Tech 
University – Health Science Center, Lubbock, TX). 
 Previous works from this same group reported differences in P-gp ATPase hydrolysis 




lipid environment condition to achieve the P-gp activity closer to its native state to test how our 
compounds would affect the drug stimulated the activity of P-gp.  
Here we report our P-gp purification attempts as well as the strategy to lipid-activate wild-
type human P-gp as well as the use of P-gp reconstituted in nanodiscs and the evaluation of the 
potential of our previously discovered drug-like compounds to serve as inhibitors of human P-gp 
ATP hydrolysis activity.   
 
4.2 Results  
The Pichia pastoris expressing human MDR1 wild type was sent to us by our collaborator 
and immediately aliquoted in bottles containing 80 mL of cells. Small aliquots of 500 μL of cells 
were also saved for future attempts to grow these cells in our lab, while aliquots of 200 μL were 
used for initial analysis. All aliquots, large and small, were stored at -80oC freezer for later usage. 
Small scale cell breakage and western blot were made to check for human MDR1 expression. After 
the confirmation of the P-gp expression, large-scale preparations were made.  
Initial attempts to purify the human P-gp from these cells using the same protocol for the 
mouse MDR3 cysteine-less 70, 86 resulted in an enriched protein with some contaminants. Small 
changes on the affinity chromatography washes (including a second wash with a 40 mM Imidazole 
buffer) yielded a successfully isolated P-gp, about 0.02 mg of P-gp/g Pichia pastoris cells (Figure 






Figure 4. 2: Human MDR1 P-gp purification steps and reconstitution into nanodiscs.  
(a) Lane 1. Final microsome fraction; lane 2. Thermo Scientific Spectra Multicolor Broad Range 
Protein Ladder (260-10 kDa); lane 3. Solubilization Pellet; lane 4. Solubilization Supernatant; lane 
5. Ni-NTA Chromatography first fraction flow-through (FT); lane 6. Ni-NTA Chromatography 
wash 1 fraction - 20 mM Imidazole (W1); lane 7. Ni-NTA Chromatography wash 2 fraction – 40 
mM Imidazole; lane 8. Ni-NTA Chromatography final elution fraction – 300 mM Imidazole (Elu) 
(~130 kDa). Top gel Coomassie blue staining. Bottom western blot image – C219 anti-P-gp 
primary antibody (Enzo Life Sciences) – lanes 7 and 8 images were photobleached due to the high 
amount of protein present. (b) Reconstitution of P-gp into nanodiscs: Lane 1: Color Prestained 
Protein Standard, broad range (10-250 kDa) NEB®; Lane 2: MSP (~26 kDa); lane 3: P-gp in 
micelles (~130 kDa); lane 4: P-gp reconstituted into nanodiscs. 
 
From the initial cells that were saved, we prepared new cultures using Fernbach flasks for 
culturing instead of the fermenter used by Dr. Urbatsch’s group on their preparations. We noticed 
the initial cell growth took longer than the regular 24 hours in the glycerol-based medium. The 
expression was not as good as the original cells, even after several attempts.  We decided to use 
enriched minimal glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% 
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growth. Under these conditions, the cells grew faster, and after 24 hours in this medium, the OD600 
was usually between 8 -14. After switching the medium from glycerol to methanol-based medium, 
expression of P-gp was observed over the time between 24-72 hours after which the cultures were 
harvested. Purification from this homegrown Pichia pastoris containing human P-gp presented 
more challenges since we observed more contaminants in the final enriched P-gp fraction (figure 
4.3 A, lane 8). When we tried to include more washes on the final steps of the chromatography 
column, we ended up losing more P-gp, so we decided to keep only 2 washes: first wash buffer 
containing 40 mM Imidazole and the second wash containing 60 mM Imidazole. Unfortunately, 
these preparations yield 0.001 mg P-gp/g of cell – significantly lower than the original cells 









Figure 4. 3: Homegrown human P-gp purification steps and reconstitution into nanodiscs 
(a) Lane 1. Final microsome fraction; lane 2. Thermo Scientific Spectra Multicolor Broad Range 
Protein Ladder (260-10 kDa); lane 3. Solubilization Pellet; lane 4. Solubilization Supernatant; lane 
5. Ni-NTA Chromatography first fraction flow-through (FT); lane 6. Ni-NTA Chromatography 
wash 1 fraction - 20 mM Imidazole (W1); lane 7. Ni-NTA Chromatography wash 2 fraction – 40 
mM Imidazole; lane 8. Ni-NTA Chromatography final elution fraction – 300 mM Imidazole (Elu) 
(~130 kDa). Top gel Coomassie blue staining. Bottom western blot image – C219 anti-P-gp 
primary antibody (Enzo Life Sciences). (b) Reconstitution of Pgp into nanodiscs: Lane 1: Thermo 
Scientific Spectra Multicolor Broad Range Protein Ladder (260-10 kDa); Lane 2: MSP (~26 kDa); 
lane 3: P-gp in micelles (~130 kDa); lane 4: P-gp reconstituted into nanodiscs. 
 
As other ABC transporters, P-glycoprotein has been reported to be activated in the presence 
of lipids mimicking their natural cell membrane environment 86. For this reason, attempts to 
activate the enriched P-gp were made to achieve the best possible activation profile (figure 4.4). 
Lipid activation was achieved after incubating the enriched P-gp with the lipid at room 
temperature at different lipid to P-gp ratios in the presence of DTT, as described in 86. As observed 
in figure 4.4, the lipid activated P-gp showed just a very slight difference in basal activity compared 
with the non-activated P-gp. A larger difference was observed when drug stimulated the activity 
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response to verapamil in a concentration-dependent manner. The protein-lipid ratio of 1:100 
seemed to be the most suitable for the next tests.  
 
 
Figure 4. 4: Lipid activation using different P-gp: E. coli lipids weight ratio.  
Samples were tested in duplicates in the presence of 5mM DTT and the assigned lipid amount 
content.  
 
As discussed earlier, nanodisc assembly of the mouse P-gp was successfully performed by 
our group and resulted in a significant increase in P-gp ATP hydrolysis activity. In hopes of 




































the ATPase hydrolysis activity between P-gp in mixed micelles both in the absence (basal activity) 
and presence (stimulated activity) of the transport substrate, verapamil. (figure 4.5).  
A successful assembly of human P-gp into nanodiscs was achieved (figure 4.2 B lane 4 
and 4.3 B lane 4) following the procedure described in 84, 93, and its initial activity was assessed 
(figure 4.5 B). Initial ATPase hydrolysis tests on P-gp reconstituted in nanodiscs showed low basal 
activity (40 nmol NADH/min/mg of P-gp). Still, a good stimulated activity in the presence of 
verapamil (100-118 nmol NADH/min/mg of P-gp), as well as some inhibitory effects of the drug, 
stimulated activity by one of the previously discovered compounds, compound SMU 29 (95 nmol 
NADH/min/mg of P-gp) that was also observed in activated P-gp (figure 4.5 A). 
Comparing the performance of lipid-activated P-gp and P-gp reconstituted into nanodiscs 
indicated a similar pattern in the response of drug stimulation activity and the inhibitory effect of 







Figure 4. 5: Effect of different conditions on P-gp on P-gp ATPase hydrolysis.  
(a) 1:100 protein: lipid ratio activated P-gp; (b) P-gp reconstituted into nanodiscs 1:500 protein: 
lipid ratio.  
 
 While the ATP hydrolysis tests showed similar activities between activated P-gp and P-gp 
in nanodiscs, there is better stability with the nanodisc preparations since its storage could keep 
the activity constant for a longer time while lipid activated P-gp could only be used freshly made 
as its activity would decrease dramatically after the freeze and thaw cycles.  For this reason, 
nanodiscs preparations were used in subsequent steps. 
We also wanted to investigate if the ratio of protein:lipid would interfere with verapamil 
stimulation of P-gp activity. To test that, we made nanodisc preparations using two different 
protein:lipid molar ratios – 1:250 and 1:500. The differences in lipid content would make the 
nanodiscs more or less compact, and this could interfere with the P-gp conformational changes 




On this test (figure 4.6), we observed that nanodiscs with any lipid content tested would 
improve the activation of P-gp in comparison with the P-gp in micelles only. The basal activity 
was better in both conditions. Still, the 1:250 nanodisc presented a better outcome, possibly due to 
the smaller size of the nanodiscs that would allow the nucleotide-binding sites to be closer, 
facilitating the ATP hydrolysis of P-gp. The drug stimulation of P-gp by verapamil was improved 








Figure 4. 6: P-gp activity on different lipid environments.  
P-gp ATPase hydrolysis activity on four different environments with or without the presence of 
VPL: P-gp in micelles, P-gp in micelles activated by L-α Phosphatidylcholine (PC), P-gp 
reconstituted in nanodiscs 1:250 P-gp:lipid ratio, P-gp reconstituted in nanodiscs 1:500 P-gp:lipid 
ratio. 
 
After the initial ATPase hydrolysis activity tests using compound SMU 29, we also tested 
the effect of the other two initial hit compounds, SMU 34 and SMU 45, on the human P-gp 
reconstituted in nanodiscs (using 1:500 Pgp:lipid ratio) to compare with the previous results 
































Figure 4. 7: Initial hit compounds effect in the human P-gp hydrolysis activity. 
Activity with P-gp using Phosphatidyl Choline (PC) (Basal activity between 91-94 nmol 
NADH/min.mg P-gp; stimulated activity between 91-123 nmol NADH/min.mg P-gp) 
 
While the effect of compound 29 on the hydrolysis activity of the verapamil-stimulated P-
gp was not as efficient on this test, a strong inhibition was observed when the compounds 34 and 
45 were used in these tests (figure 4.7 B). Additional tests were made using compound 29 to 
confirm its inhibitory effect on the ATPase hydrolysis of the drug-stimulated P-gp (see chapter 5). 
 
4.3 Methods and materials 
4.3.1 Growth of P. pastoris human MDR1 wild-type P-gp 70, 75, 76, 86, 98:  
Cells were grown using the methods previously described in Invitrogen for PichiaPinkTM 
70, 75, 76, 86. In short, A single colony from a YPD agar plate (1.34% Yeast Nitrogen Base (YNB), 
4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 mL of liquid Enriched Minimal 
Glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 1% glycerol, 
4x10-5% Biotin, 100mM Potassium Phosphate) and incubated at 28oC with shaking to an OD600 of 




Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was continued (~24h), then 
the cultures were centrifuged into sterile bottles (6000 rpm at JXN-16 centrifuge, JLA 8,100 rotor 
for 7 min at 23oC). Protein production was induced by switching the carbon source of the medium 
from glycerol to methanol. The cells pellets were resuspended in 1 liter of enriched Minimal 
Methanol (BMMY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 4x10-5% 
Biotin, 0,5% v/v methanol, 100mM Potassium Phosphate) in 2-liter Fernbach flasks covered with 
cheesecloth. Incubation continued for 72h with the addition of methanol (1% v/v) at 24 and 48 
hours.  The pH correction was adjusted to ~6.0 if needed. Cells were finally collected by 
centrifugation at 6000 rpm for 7 min at 4oC and resuspended in ice-cold “homogenization buffer” 
(0.33 M sucrose, 0.3 M Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-
aminocaproic acid) at a concentration of 1g wet cells/mL buffer. The cells were stored at -80oC 
4.3.2 Microsome preparation from yeast cells:  
Microsomes were prepared essentially as described in 86, with the modifications made in 
70, 75, 76. Frozen cells were rapidly thawed by incubating bottles in a water bath set at 28-30oC for 
~10 min, swirling the bottle's content to equilibrate the temperature. Lysozyme from T. Harzanium 
was added while the cells were thawing to improve the cell lysis. All further steps were performed 
at 4oC or on ice. Protease inhibitors were added once the cell suspension was thawed as follow 2 
µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml PMSF, and 10 µl/ml 
DTT. All the cells were transferred to a chilled bead beater apparatus that was filled to top with 
“buffer A1” (30% v/v glycerol, 50 mM Tris-HCl, pH 8, 125 mM NaCl, 10 mM imidazole) 
supplemented with DTT (10 µl/mL). Cells were mechanically disrupted by using 0.5 mm glass 
beads in a bead-beater (BioSpec) for a total of 14 minutes. The bead-beater was attached to a 




disruption was performed in 7 cycles of 2 minutes bead beating alternated with 6 minutes with the 
bead-beater “off” to allow cells to cool down. This method helped solve the problem of overheated 
samples due to the high heat output of the bead-beater motor. The homogenate was then 
centrifuged for 30 minutes at 10,000 rpm (at Beckman J21-M equipped with a JA-20 rotor), and 
the pellet was discarded. These steps removed unbroken cells, nuclei, and mitochondrial fractions. 
The supernatant was centrifuged at 45,000 rpm (at Beckman Optima LE-80K equipped with Ti70 
or Ti55.2) for 45 min at 4oC. After this ultracentrifugation, the supernatant contained cytoplasmic 
protein and was discarded. The resulting pellet containing the microsomes was resuspended in 
“wash buffer” (20% v/v glycerol, 50 mM Tris-Cl, pH 7.4 at 4oC, and protease inhibitors – 1 mM 
PMSF, 1 mM DTT, Pepstatin A, Leupeptin, and Chymostatin as above). The microsomes were 
recentrifuged at 45,000 rpm at Beckman Optima LE-80K equipped with Ti70 or Ti55.2) for 45 
min at 4oC.  The supernatant was discarded, and the pellet was resuspended initially using a 
paintbrush then by 10 strokes by hand in a Potter-Elvehjem Teflon pestle homogenizer in 30 mL 
of “buffer A1” plus protease inhibitors as before). The microsomes were then frozen at -80oC.  
4.3.3 P-gp Purification:  
Purification of the transporter protein was performed essentially as described in 70, 75, 76, 86, which 
successfully resulted in highly enriched mouse (MDR3) P-gp in mixed micelles. The microsomes 
were quickly thawed in a circulating water bath set at 28-30oC and then eluted to a final 
concentration of 4mg microsomal protein/ml with “buffer A2” (20% v/v glycerol, 50 mM Tris-
HCl, pH 8.0 at 4oC, 50 mM NaCl, 10 mM imidazole, plus protease inhibitors as follow: 2 µg/ml 
pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 1 mM PMSF). Further dilution of the 
sample to a final concentration of 2 mg microsomal protein/mL was achieved by adding a 




(w/v) n-dodecyl-β-D-maltoside, DDM (Inalco), and 0.02% (w/v) lyso-phosphatidylcholine, Lyso-
PC (Lipoid GmbH). DDM and lyso-PC were added to facilitate micelle formation, providing a 
more native environment during the purification process. Sonication of samples at 4oC for 4 cycles 
of 5 minutes each in an ultrasonic bath filled with ice/water, interspersed with 5 minutes incubation 
in an ice bucket on a rocking platform, was performed to allow protein solubilization. The 
suspension was then centrifuged at 20,000 rpm for 30 min at 4oC (Beckman Optima LE-80K 
equipped with Ti 70 or Ti 55.2 rotors) to remove insoluble material. The supernatant was then 
applied to the pre-equilibrated Ni-NTA agarose resin (Qiagen) column at a ratio of 100 mg 
microsomal protein per 1ml packing resin (one bed volume). The rest of the procedure was 
performed at 4oC. The chromatography gel and solubilized protein solution were mixed and 
incubated for 10 minutes before the column was poured. The flow-through was ~2ml/min. The 
resin with bound P-gp was washed first with 20 bed-volumes of “Column wash buffer 1” (20 % 
glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50mM NaCl, 20mM Imidazole, supplemented 
with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 % (w/v) lyso-PC/mL buffer), followed by 10 bed-
volume of “Column Wash buffer 2” (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50 
mM NaCl, 40 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 % 
(w/v) lyso-PC/mL buffer). For both washes, the flow-through was ~1ml/min.  P-gp was then eluted 
with 3 bed-volumes of Elution buffer (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC, 50 
mM NaCl, 300 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 % 
(w/v) lyso-PC/mL buffer) with a ~0.5 ml/min flow rate. All eluted protein was collected for the 
next step.  To obtain concentrated P-gp, the elution fraction from the Ni-NTA column was 
concentrated 70- to 100-fold using Amicon centrifugal filters (Amicon/Millipore Corp., Billerica, 




micelles and ensures retained solubilization of the membrane protein, resulting in concentrated, 
enriched, and solubilized protein for use in nanodisc assembly. The protein was aliquoted in 40µl, 
ready to be used in nanodisc assembly, and stored at -80oC.  
4.3.4 Lipid activation:  
Activation of P-gp was performed under varying conditions. As suggested by 70, 86, ~8 mM 
Dithiothreitol (DTT) was added to purified P-gp with subsequent incubation on ice for 5 min. 
Lipids were added at different concentrations and incubated at room temperature for 15 min. After 
the incubation, the samples were sonicated at 4°C for 30 seconds and kept on ice until used in 
ATPase assay. In separate experiments as described in 86, activation was performed in the absence 
of DTT.  
4.3.5 Nanodisc Assembly and Recovery 84, 85:  
  P-gp in mixed detergent micelles obtained during protein purification was assembled as 
described in Chapter 2 – Material and Methods. 
4.3.6 Assays of ATPase activity – Coupled-enzyme assay 70:  
The activity assay for ATP hydrolyzing enzymes was developed by 74,  as described in 
Chapter 2 – Material and Methods. 
4.3.7 Drug inhibition assays 70, 74-76:  
A total volume of 5 ul containing 25 µM of experimental compounds dissolved in 
dimethylsulfoxide (DMSO) was added to each well along with 45 ul of equilibration buffer (20% 
glycerol, 50 mM Tris H-Cl, pH 7.5), in a 96-well plate. To each of these wells, 50 µl of the solution 
containing 80-100 µg/ml concentrated P-gp incorporated into nanodiscs, in equilibration buffer in 
the absence or presence of 300 µM verapamil. The plate was incubated at 37oC for 30 min before 




ATPase activity – Couples-enzyme assay). Immediately after addition, ATPase activity was 
assayed for 20-30 min. ATP hydrolysis was recorded as absorbance decrease at 340 nm (ε=6300 
M-1 cm-1), using a BioTek plate reader (BioTek, Winooski, VT). All tests were performed in 




To evaluate the mechanism of inhibition in the human P-gp, we have isolated human P-gp 
from the yeast Pichia pastoris using mixed detergent micelles. The P. pastoris cells containing 
human P-gp received from Dr. Urbatsch (Texas Tech University Health Science Center, Lubbock, 
TX) was grown by a large fermenter, which resulted in cells with relatively high P-gp expression, 
as was seen after purification and providing about 0.02 mg protein/g of cells of yield as well as 
higher ATPase activities of P-gp both in micelles and nanodiscs. The final P-gp fraction presented 
few or no contaminants, and a simple additional wash (40 mM imidazole buffer) was sufficient 
during the purification using the chromatography resin Ni-NTA. Even though there were losses of 
protein during each purification fraction, the high protein yield in the final fraction was sufficient 
to proceed with our tests.  
The same expression and yield were not observed in our attempts to grow the cells in-house 
using the 2.8 liters Fernbach flasks at 28oC incubators. This observation made us modify our 
washing steps during the purification process and attempts to ensure better expression and fewer 
contaminants in the final P-gp fraction. Additional wash steps resulted in large losses of the protein 




somewhat better results. Using the first wash with 40mM imidazole buffer and a second wash with 
a 60 mM imidazole buffer resulted in slightly more enriched protein. 
As described by others 86, the presence of lipids is required to achieve higher P-gp ATPase 
activity. On our initial tests, P-gp basal activity was slightly enhanced by the addition of lipids or 
upon nanodisc assembly (figure 4.4). Nanodisc assembly showed better stability of P-gp and less 
loss of activity than the lipid-activated samples after freezing. Verapamil-stimulated activity 
increased both upon lipid-activation of P-gp and P-gp reconstitution into nanodiscs. As native 
membrane proteins are found embedded in a lipid environment, this variation observed on the 
ATPase activity of purified P-gp could be due to different intrinsic lipid content in the preparations. 
P-gp reconstituted into nanodiscs was the lipid activation method used from here.  
To investigate potential differences between the human and mouse versions of P-gp, we 
replicated the tests' conditions with mouse MDR3 Cysteine-less P-gp using the human P-gp variant 
reconstituted into nanodiscs. The results showed that the basal activity was slightly affected (range 
activity in nmol NADH/ min.ng P-gp) by the compounds 29,34 and 45 (figure 4.7 A), similar to 
what was found in 70. While the effect of compound 29 on the hydrolysis activity of the verapamil-
stimulated P-gp was not as strong in these initial tests, a strong inhibition was observed when the 
compounds 34 and 45 were used (figure 4.7 B). Additional assays were made using compound 29 
to confirm its inhibitory effect on the ATPase hydrolysis of the drug-stimulated P-gp (chapter 5). 
CHAPTER 5:                                                                                                                                      
DRUG SCREENING FOR P-GLYCOPROTEIN INHIBITORS  
 
5.1 Introduction  
 In 2021, the American Cancer Society estimated almost 2 million new cancer cases to be 
diagnosed in the U.S and over 600,000 cancer deaths in the U.S. 118. Even though we are making 
great progress in our understanding of the mechanisms of how cancer works, we still cannot 
prevent it from happening. Improvement in cancer treatment might therefore be considered an 
easier goal to achieve. Some of the main challenges for successful cancer treatment are related to 
the variety of ways that cancer cells develop ways to evade therapy, i.e., ways to become resistant 
to chemotherapy drugs.  
 As mentioned previously (see chapter 1), a great contributor to chemotherapy failure is 
multidrug resistance (MDR) mediated by the overexpression of ATP-dependent efflux transporters 
that prevent the drug accumulation inside the cell, promoting cancer survival  12.  
 The search for inhibitors of P-glycoprotein – the most studied of these transporters - did 
not bring much hope over the last decades 119. To date, most of the inhibitor candidates were found 
to be substrates of P-gp. Since they work as competitive transport inhibitors, high concentrations 
were necessary for the desirable inhibitory effect, leading to unacceptable toxicity. Another 




causing drug-drug interactions 119, 120.  Better methods to screen for good drug lead candidates to 
overcome these limitations were addressed in recent studies performed by our group 2, 33, 70. 
Crystal structures and homology models of P-gp allowed the utilization of targeted 
screening and molecular dynamics simulations 31 for drug docking experiments 55, 56.  
We have previously identified a group of compounds that were hypothesized to prevent 
hydrolysis of ATP by P-gp but to not be substrates of P-gp 31 (see chapter 4), and several drug-like 
compounds were discovered 33, 70, 80 (figure 1 a). We hypothesized that improving the binding 
characteristics of a previously identified P-gp inhibitor would lead to a more successful drug 2 
(figure 1 b). 
Compound SMU-29, a P-gp inhibitor previously identified 70, was predicted to bind to a 
site on P-gp that is distinct from the ATP binding sites of the pump. This characteristic made the 
compound an interesting candidate for further development since it lowered the likelihood of 
negative effects on other ATP utilizing enzymes and lowered the chance for side effects of the 
potential drug. Close inspection of the docking site of SMU-29 in the putative allosteric site on P-
gp indicated that there was space available for additional interactions between the protein and 
SMU-29. Modifications to SMU-29 that would fill this space and create additional 
protein/compound interactions were hypothesized to increase the binding affinity of these SMU-





Figure 5 1: Compound 29 and the rationale for its structure modification. 
(A) Predicted binding site of compound SMU-29. Figure reproduced from70. Location of docked 
inhibitors in the human P-gp model. On the left is the location where the nucleotides are bound. 
On the right, the approximated location of the highest affinity interaction of P-gp inhibitors is 
predicted by docking studies 70. SMU-29 (top right) is bound outside the nucleotide-binding sites 
suggesting an allosteric effect causing inhibition of ATP hydrolysis likely by blocking 
conformational transitions of the enzyme. (B) Schematic plan for the compound 29 modification: 
structure of compound 29, the “Eastern” and “Western” portions of the molecule, the docking of 
the potential allosteric site, and the possible modifications. Figure reproduced from 2. 
 
Assessment of the docking profile indicated that “filling” additional space, especially 
around the “Western” end of the compound, would create new and better protein-compound 
interactions. (figure 5.1)  2. Experiments were designed to alter this specific part of the compound 
for additional interactions with P-gp and binding affinity optimization. Using in silico medicinal 




and binding affinities were predicted 2, several variants of SMU-29 were chosen for chemical 
synthesis. In addition, close inspection of the binding interactions of SMU-29 with the binding site 
on P-gp led to the synthesis of several more rational structure-based designed variants of hit 
compound 29 2. 
 
5.2 Results 
5.2.1 Optimizing in silico identified targeted inhibitors of P-gp 
The chosen variants of SMU-29 were synthesized by Dr. Maha Aljowni and Professor Alex 
Lippert, Department of Chemistry, SMU. Cell culture experiments using the P-gp overexpressing 
human prostate cancer cell line, DU145.TXR (19) indicated that all of these compounds reversed 
multidrug resistance 2. 
The effect of the SMU variants on ATP hydrolysis activity of P-gp was initially assessed 
using the mouse cysteine-less P-gp 2, which had been found by our lab to be somewhat more stable 
than the human homologous protein. The experiments suggested that one compound (-551) from 
the computationally screening group may be a transport substrate because it stimulated the basal 
P-gp ATPase activity,121, 122, while from the rationally designed group, only the compound -231 
presented similar results.  
To evaluate the effects of the 29 variants on ATPase activity of normal, cysteine-containing 
human P-gp, P-gp was expressed in Pichia pastoris and reconstituted into membrane nanodiscs as 
described in chapter 4. Fig. 5.2 shows the results of these experiments. ATP hydrolysis in the 




MDR1 P-gp was between 123 and 193 nmol min-1g-1, and transport substrate (verapamil) 
stimulated activity was between 193-263 nmol min-1mg-1. 
The studies indicated that all SMU-29 variants inhibited verapamil-stimulated ATPase 
activity (figure 5.2 and table 5.1). SMU-29 variants -216, -231, and -551 inhibited basal activity, 
while the other compounds had no effect. None of the compounds were found to stimulate ATP 
hydrolysis activity. It had been generally assumed that ATP hydrolysis is stimulated in the 
presence of transport substrates 31, 123. The lack of stimulation of ATP activity by any of the SMU-
29 variants therefore tentatively suggested that none of these compounds were transport substrates 
of the pump.  
 
 
Figure 5 2: ATPase activity of nanodisc reconstituted P-gp after incubation with 29 variants.  
(A) Effect of the 29 variants on basal activity P-gp. B. Effect of the 29 variants on verapamil 
stimulated the activity of P-gp in nanodiscs. The data were normalized to vehicle (DMSO) only 
activities (3 independent experiments with duplicate samples).  (***, p < 0.001; **, p < 0.01; *, p 










Table 5 1Table 5.1: Summary of the effects of the compound 29 variants on ATP hydrolysis by 




To test the hypothesis that the lack of stimulation of ATP hydrolysis activity by the 29-
variants indeed suggested that these compounds were not transport substrates, intracellular 
accumulation of the 29 variants in P-gp overexpressing cancer cells was measured comparison 
with the P-gp transport substrate, daunorubicin. In collaboration with Dr. Noelle Williams from 
UTSW Preclinical Pharmacology Core, we used LC-MS/MS to quantify the intracellular 
accumulation of the compounds in the absence or presence of the strong P-gp inhibitor tariquidar 
(TQR) in the P-gp overexpressing prostate cancer cell line (DU145 TXR). These experiments 
strongly suggested that none of the five SMU-29-variants that were computationally designed and 




compounds that were rationally designed with no computational pre-screening, three variants ( -
238, -255, -286) were likely transport substrates of P-gp 2. This finding strongly indicated that 
stimulation of P-gp ATPase activity is not a good indicator for a compound being a transport 
substrate or not. Other types of experiments are needed to make that assumption. The studies also 
showed that structure-based rational design without computational pre-screening using the 
subtractive method first described in 70 does not result in reasonable predictions on whether or not 
the variants will be transport substrates of the pump 2. 
 
5.2.2 Biochemical and biophysical evaluation of in silico identified P-gp inhibitors. 
 From a total of 124 compounds that were computationally identified as potential P-gp 
inhibitors and that were assessed in our lab, 16 compounds (57, 60, 61, 66, 68, 70, 71, 74, 78, 79, 
96, 97, 101, 111, 114 and 124) were deemed to be the most promising hit compounds by their 
ability to reverse multidrug resistance in various P-gp overexpressing cancer cell lines 
(McCormick et al., unpublished) in addition to the three initially identified inhibitors SMU 29, 
SMU34 and SMU 45 70. These 16 compounds were further evaluated for their effect on ATP 








Figure 5 3: Effect of the hit compounds on ATP Hydrolysis of Human MDR1 P-glycoprotein.  
Results are presented compared to DMSO control ± standard deviation (2 independent experiments 
with triplicate samples). The specific basal activity of normal human MDR1 P-gp was between 
171 and 235 nmol NADH min-1 mg of P-gp -1, without a transport substrate. (***, p < 0.001; **, 
p < 0.01; *, p < 0.1; NS, not significant) 
 
 
The presence of DMSO carrier was used as 100 % activity, and the presence of SMU-45 
70 was used as a positive control for P-gp ATPase inhibition. Compounds 57, 60, 68, 71, and 74 
showed significant inhibition of ATP hydrolysis, while all other compounds either stimulated 
ATPase or did not exhibit significant effects. 
To evaluate whether the compounds that inhibited ATP hydrolysis indeed affected 
nucleotide binding, electron spin resonance spectroscopy (ESR) using a spin-labeled ATP analog, 













































































We have used ESR previously to evaluate the mechanism of inhibition of P-gp activity by 
discovered inhibitors 70. Using SL-ATP, the number of accessible ATP binding sites on P-gp can 
be assessed 70. 
Using the normal human P-gp, titrations of P-gp with SL-ATP were performed, and the 
binding of SL-ATP to P-gp was determined in the absence and presence of two of the most 
promising P-gp inhibitors, compounds 70 and 111 (figure 5.4).  
 
 
Figure 5 4: SL-ATP binding to human P-gp. 
(A) P-gp SL-ATP titration. (B) SL-ATP titration in the presence of the compound 111 (top panel) 
and compound 70 (bottom panel)  
 
Interestingly, titration of the normal cysteine-containing human P-gp resulted in binding 




experiments where the cysteine-less mutant of the mouse P-gp was used 2, 75. However, the binding 
of SL-ATP was significantly reduced in the presence of inhibitors 70 and 111, indicating the direct 
effect of these compounds on SL-ANP binding. The phenomenon of SL-ATP binding curves to P-
gp that do not saturate at a maximum of 2 mol/mol has been observed previously when ATP 
binding a normal, cysteine-containing mouse P-gp was evaluated. This phenomenon will be 
discussed later. 
5.2.3 Other inhibitors of P-glycoprotein 
 In collaboration with Amit Tiwari, College of Pharmacy and Pharmaceutical 
Sciences, Department of Pharmacology and Experimental Therapeutics of the University of 
Toledo, several compounds were tested for their effects on ATP hydrolysis. These compounds 
were originally designed in the Tiwari lab as inhibitors of the second important multidrug 
resistance protein, BCRP. They were shown in cell culture to cause cell death in BCRP, 
overexpressing cancer cells in the absence of chemotherapeutics while not affecting non-cancerous 
cells that do not overexpress BCRP (unpublished). While the compounds were designed to interact 
with BCRP, it was interesting to investigate whether these compounds also interacted with P-
glycoprotein. 
Initial ATP hydrolysis assays using the normal, human P-glycoprotein indicated that all 
experimental compounds affected ATPase activity (figure 5.5).  These results are important 






Figure 5 5: Effect of the Tiwari’s compounds on ATP Hydrolysis of Human P-glycoprotein.  
Results are presented compared to DMSO control ± standard deviation The specific basal activity 
of normal human MDR1 P-gp was between 171 and 235 nmol NADH min-1 mg of P-gp -1, 
without the presence of a transport substrate. (n=4, two independent tests; ***, p < 0.001; **, p < 
0.01; *, p < 0.1; NS, not significant). 
  
5.3 Methods and materials 
5.3.1 ATPase activity assay using activated P-gp in micelles and reconstituted P-gp into 
nanodiscs:  
ATP hydrolysis activity was measured using a Coupled Enzyme Assay (CEA) adapted to 
a plate reader format 70, 74 as described earlier with the following modifications: To each well, 0.5-
2 µg of P-gp incorporated into nanodiscs were added in the absence or presence of 100 µM 

































































5.3.2 Drug inhibition assays:  
As described in 70, the effects of the in silico identified potential inhibitors and the 
compounds from Dr. Tiwari’s group on P-gp were assessed at 25 µM of the experimental 
compounds dissolved in dimethylsulfoxide (DMSO) in assays as described above. Vehicle DMSO 
only was used as a control. 
5.3.3 Electron spin resonance:  
 ESR measurements were performed using a Bruker EMX 6/1 ESR spectrometer operating 
in the X-band mode, equipped with a high sensitivity cavity, essentially as described 75. Human P-
gp was concentrated to 30 µL, and known amounts of SL-ATP were added to the protein sample 
using a Hamilton syringe. After careful mixing, 30 µl of the sample was transferred to a 50 µl glass 
capillary. The top of the glass tube was closed, and it was inserted into a quartz cuvette. The cuvette 
was then placed in the ESR cavity, and the measurements were made at room temperature.  The 
measurements were made with constant parameters: microwave frequency 9.33 GHz, modulation 
frequency 100 kHz, resolution 1024 points, microwave power 12.63 mW. The signal gain was 
adjusted to the SL-ATP concentrations for better visualization. The buffer was the same as used 
to elute P-gp from the chromatography column (see chapter 4, Material and methods section 4.3.3). 
A standard curve was generated where known amounts of SL-ATP were added to the buffer that 
was concentrated similarly to the protein sample to control for increased viscosity of the 
detergent/mixed micelle solution. The signal amplitude of the high-field signal of the ESR spectra 
was compared to the known amount of SL-ATP added. The moles of protein-bound ATP were 
then determined as the difference of signal amplitude in the presence of a known amount of P-gp 




mol of protein was plotted over the concentration of free SL-ATP present. Results were plotted 
and calculated using Graphpad. 
 
5.4 Discussion 
We had previously used high-throughput in silico ligand docking studies and identified 
drug-like compounds that reversed MDR in human cancer cells in cultures 1, 70, 80. The effects on 
P-gp ATP hydrolysis activity were also assessed at that time. These results were used as an initial 
biochemical evaluation of the mechanism of inhibition by these compounds. For these initial 
experiments70, 124, a cysteine-less mutant of the mouse homolog of P-gp was used due to its 
somewhat increased stability compared to the human protein. Interestingly, effects on ATP 
hydrolysis did not always correlate well with the effects of the potential inhibitors in the cell culture 
of human cancerous cells. One hypothesis was that the mouse protein, although 87% homology 45, 
may be different enough to not be a good model for assessing inhibitor effects on the human 
protein. To overcome the low stability of the human protein, the human P-gp was assembled into 
nanodisc to provide a more nature-like membrane environment to maintain its active form for the 
activity assays.  
For the 29-variants biochemical assays using purified human P-gp reconstituted in 
nanodiscs, compounds from both groups inhibited drug stimulated activity of P-gp (figure 5.3).  
None of the new compounds stimulated the basal activity, suggesting no interaction with the drug 
binding sites. Some of them inhibited P-gp basal activity, even though LC-MS/MS data (figure 
5.4) indicated four of them to be transport substrates. These findings suggested that stimulation of 





The experiments using LC-MS/MS to test for the quantitative cellular accumulation of the 
29-variants in the presence of the P-gp inhibitor, tariquidar, indicated that none of the compounds 
from the computationally screened group was a transport substrate. In contrast, from the rationally 
designed/not computational screen group, 3 of the 5 compounds were likely P-gp transport 
substrates 2.  
Aside from the biochemical assays to measure ATPase activity, the results also indicate 
the successful approach of the computational screening and analysis in optimizing P-gp inhibitors 
2. 
Next, another set of compounds were screened for potential P-gp ATPase hydrolysis 
inhibitors. Most of these compounds chosen for the biochemical assay affected the ATPase activity 
of P-gp at some level (inhibition or stimulation), suggesting the successful approach to the 
improved drug screening (figure 5.3). The next step would be to assess if they interact with the 
nucleotide-binding domain using electron spin resonance.  
ESR spectroscopy is a technique that detects unpaired electrons. Due to the low occurrence 
of paramagnetic species in biological systems, spin-labeled nucleotides (SL-ATP) were introduced 
78.  
In our experiments, it was not possible to determine the binding characteristics of SL-ATP 
to the human cysteine-containing P-gp. As shown in figure 5.4 a, the binding curves of SL-ATP 
to the human P-gp extrapolated significantly beyond the predicted maximum binding of 2 mol/mol. 
A similar phenomenon was observed previously by our group when the wild-type, cysteine-
containing mouse P-gp variant was tested using ESR 75. In these experiments, the binding of SL-
ATP also significantly exceeded the expected 2 mol/mol. The hypothesis at that time was that SL-




interaction likely resulted in a chemical reduction of the radical 75, 87, leading to a decrease of the 
signal amplitude of the ESR spectra mimicking binding of the SL-ATP to P-gp. This hypothesis 
was then supported by experiments where a cysteine-less variant of the mouse P-gp was used. In 
the absence of cysteines, maximum binding of SL-ATP of 2 mol/mol P-gp was observed. 
In the presented experiments, the fact that the two P-gp inhibitors, compounds 70 and 111, 
drastically decreased the binding of SL-ATP to P-gp strongly suggests that these compounds affect 
nucleotide binding to P-gp. Repeating these experiments with a cysteine-less mutant of the human 
P-gp will be needed for further confirmation. 
Our collaborative work with the Tiwari lab (University of Toledo) indicated that 
compounds designed and synthesized in their group that were supposed to specifically interact 
with the breast cancer resistance protein (BCRP) also affected ATP hydrolysis of purified human 
P-gp. These findings will be of importance for the design of future experiments and drug 
development. 
CHAPTER 6:                                                                                                                                       
THE CHALLENGES OF PRODUCTION AND PURIFICATION OF THE ABC 
TRANSPORTER BREAST CANCER RESISTANCE PROTEIN (BCRP) ON LARGE SCALE 
USING THE YEAST PICHA PASTORIS. 
 
6.1 Introduction 
One of the most studied ABC transporters, the Breast Cancer Resistance Protein (BCRP), 
was first discovered by its expression in MCF7 breast cancer cells 125.  Since then, it was found 
that BCRP is expressed in many tissues, including those with a barrier or detoxifying functions 
such as placenta 126, cerebral endothelium 127, apical membrane of the polar epithelial cells in 
intestine 128, liver 129, kidney 130, and also blood-brain barrier 131, 132. BCRP actively exports a 
diverse range of chemicals and toxins from the cells, preventing chemotherapeutics from 
accumulating to the concentration required to kill cancer cells. BCRP plays a protective role 
against xenobiotics and their metabolites entering vital organs in the human body 130. Besides its 
known function in MDR, BCRP also exports steroids such as cholesterol, progesterone, and 
testosterone 133-137.  
The ABC transporter BCRP belongs to the ABCG subfamily. It is encoded by the ABCG2 
gene located at chromosome 4q22. Expression results in a 2.4 kb mRNA encoding 655-amino acid, 
72 kDa polypeptide localized to the plasma membrane 138, 139.   
The BCRP is expressed as a single polypeptide containing only a single transmembrane 




(NBD) (figure 1) 140.  BCRP is considered a half transporter and needs to dimerize to gain full 
functionality. The binding and hydrolysis of the two ATP molecules by two NBD in conjunction, 
where both are using the missing structural elements from the opposing NBD in a complementary 
fashion, induce the conformational change necessary for substrate transport TMD 141, 142.  BCRP 
is mostly found as homodimers, but it may function as a homotetramer in the plasma membrane 
143.  The NBD and the TMD are connected by two α-helices – connecting helix and coupling helix 
141. As a unique structural feature of BCRP, there is a longer extracellular loop (EL3) between 
TM5 and TM6 that bears three cysteine residues that form an intramolecular (C592-C608) and an 
intermolecular (C603-C603’of opposing monomers) disulfide bond that is important in the 
stabilization of dimerization of BCRP 144, 145. 
 
 
Figure 6 1: BCRP 3D structure and transport cycle of BCRP 
Figure modified from Manolaridis et al (2018). The structure is showed as a dimer of two BCRP 






Given its role in MDR, inhibitors of BCRP have been studied for years12, 125, 126, 129, 131, 132. 
To search for BCRP inhibitors as potential leads for developing co-therapeutics to combat 
MDR, we used high-throughput in silico ligand docking similar to studies performed previously 
in the search for inhibitors of the P-glycoprotein (P-gp)70, 80. Using molecular models of P-gp and 
BCRP, we identified drug-like compounds that reversed MDR in human cancers 1, 70, 80. Several 
drug-like compounds were identified that reversed multidrug resistance in a BCRP-overexpressing 
breast cancer cell line generated in our lab. Biochemical assays using purified BCRP would 
provide important information regarding the mechanism of inhibition. Such assays have been 
successfully used as primary screens in our P-gp drug finding process 70. For these purposes, 
relatively large amounts of protein are required to perform these assays. Expression of human 
BCRP in Pichia pastoris in a biologically active form was previously reported 146. In our group, 
we decided to design a gene for human BCRP optimized for codon usage for translation in P. 
pastoris, similar to the work done in 82 for P-gp expression.  
Obtaining BCRP in a near native-like environment with high biological activity will be 
necessary for the assessment of efficiency as well as the mechanism of BCRP inhibition of our 
newly found drug-like compounds.  In this chapter, strategies for cloning and expression of BCRP 
on a large scale will be discussed. 
 
6.2 Results 
 6.2.1 Cloning and expression in PichiaPinkTM and GS115 Pichia pastoris strains. 
Following the same procedures applied for the P-gp codon-optimized cloning (see Chapter 
3), a new BCRP clone optimized for translation in P. pastoris was synthesized and inserted in the 




were incorporated into the BCRP DNA sequence to allow cloning into pUC57 and PichiaPinkTM 
vectors. The pUC57-BCRP was transformed into NEB 5-alphaTM to allow replication of the 
multicopy vector. Both pUC57-BCRP and pPinkHC were double digested with the restriction 
enzymes KpnI and EcoRI to generate complementary ends. This BCRP DNA sequence was 
removed from the initial plasmids and then inserted into pPinkHC plasmids and transformed into 
NEB 5-alphaTM. Plasmids were linearized by SpeI before integration into PichiaPinkTM strains 1 
and 4 (see Chapter 3 for the methodology used on P-gp cloning). The PCR product of genomic 
DNA from transformed PichiaPink™ Strain 4 yeast strains was observed in 0.6% agarose gels 
(figure 6.2).  AOX1 and CYC1 primers were used to probe genomic DNA for the presence of the 
predicted 2.37 kb PCR product.  The plasmid control was a PCR product using the same primers 
to probe the pPinkHC-BCRP vector for the same insert size. Western blot confirmed protein 
expression on mini microsome preparations from the pilot cultures prepared and from a large 
microsome preparation (figure 6.2 b) using the B1 anti-BCRP antibody (Santa Cruz). The BCRP 
cloning procedures into PichiaPinkTM cells and initial purification attempts were made previously 
by Collette LaVigne (unpublished) (figure 6.2), and difficulties for the purification of BCRP were 
reported. In these attempts, the final elution step during the purification preparation did not show 
noticeable BCRP protein (figure not shown). Western blot analyses indicated a consistent loss of 
BCRP protein during the purification procedure (figure 6.2 b). Some of the losses were observed 
during the initial solubilization and before the affinity chromatography step. Attempts to solubilize 
the sample were made using different concentrations of the detergents. Lyso-PC and DDM did not 
provide improvements. The use of the detergent Fos-choline 16 only showed very slight 





Figure 6 2: BCRP gene in PichiaPink strain 4.  
(A) Integration of BCRP gene in transformed PichiaPink strain 4. PCR product of genomic DNA 
~2.2 kb. (B) Expression of BCRP confirmed during the growth in the methanol-based medium – 
Western blot B1 anti-BCRP antibody – Data from Collete LaVigne M.S. dissertation thesis (2017). 
 
 Before optimizing protein purification, we accessed whether the BCRP expressed in 
PichiaPink membranes was catalytically active, and initial ATPase hydrolysis activity tests were 







Figure 6 3:Initial ATPase activity of BCRP on PichiaPink membranes.  
ATPase activity assays were performed as described in 74. 0.2 mM EGTA and 8 mM NaN3 were 
included in the ATPase cocktail mix to prevent activity from other ATPases.  
 
The ATP hydrolysis activity of untransformed PichiaPink strain 4 (PPink4) in the absence 
and presence of 1 µM Hoechst, as transport substrate of BCRP, are shown in panels 1 and 2. No 
stimulation of ATPase activity in the presence of Hoechst was observed in the untransformed 
strain. The ATP hydrolysis activity of the PichiaPink4-BCRP transformants (PPink4-BCRP) is 
shown in panels 3 and 4, in the absence and presence of 1 µM Hoechst. Stimulation of ATP 
hydrolysis is observed in the presence of Hoechst. The data are averages from three replicates per 
sample. The results indicated that biologically active BCRP had been inserted into the PichiaPink 
membranes. 
Even though the PichiaPink expressed BCRP was biologically active, there still remained 
the problem described above, that the membranes seemed very hard to solubilize. Most of the 
BCRP remained in insolubilized form, making further purification problematic. We, therefore, 




Following the steps used for the MDR1 cloning into GS115, adapter primers bcrp-pink-to-
hil forward/reverse were designed to add the sequences for SacII and XhoI restriction before and 
after the BCRP DNA sequence from the pPinkHC-BCRP plasmid (figure not shown). The BCRP 
gene sequence with the complementary ends was then removed from the original plasmid. The 
BCRP insert, and the plasmid pHIL-E556C were double digested with the restriction enzymes 
SacII and XhoI to generate complementary ends. Both insert and vector were ligated and 
transformed into NEB 5-alpha cells. Transformants were screened, and the one clone containing 
the verified BCRP sequence was linearized with NotI and desalted. Integration into the GS115 
cells was achieved by electroporation, and selection of the transformants was made by screening 
for the Muts and His+ phenotype and PCR, as described in Chapter 3 – P-gp cloning 
BCRP internal primers were used to confirm the presence of BCRP DNA in the 
transformant, generating a PCR product of the size ~ 1564 bps, and pHIL primers to confirm the 
complete BCRP DNA insert, resulting in a PCR product of the size ~ 2970 bps. Four different 
colonies (#9-12) were evaluated (figure 6.4 a). Sample 12 presented the best outcome, the BCRP 
sequence was verified, and BCRP expression was confirmed from the pilot cultures (figure not 
shown).  
To assess the best possible conditions for growth and expression, two cultures were 
prepared with different culture media: the first followed the original protocol, and cells were grown 
in minimal glycerol medium (MG – YNB, Biotin, Glycerol)/minimal methanol medium (MM – 
YNB, Biotin, 0.5%$ methanol) while the second one was grown on enriched medium as suggested 
for PichiaPinkTM cells (BMGY – 1% Yeast extract, 2% bacto peptone, 1mM Potassium Phosphate, 
1.34% YNB, 0.0004% Biotin, 1% Glycerol/ BMMY - 1% Yeast extract, 2% bacto peptone, 1mM 




for 24 hours in MG/BMGY. The medium was then replaced by MM/BMMY to induce protein 




Figure 6 4: BCRP DNA screening and pilot expression tests in Pichia pastoris GS115.  
(A) Integration of BCRP gene in transformed GS115 yeast strain. - Lanes 1 & 2: pHIL-BCRP 
template controls; Lanes 3 & 5: colony #9; Lane 4: 1 kb GeneRuler DNA marker; Lanes 6 & 7: 
colony #10; Lanes 8 & 9: GS115-BCRP #11; Lanes 10 & 11: GS115-BCRP #12. (B) Expression 
of BCRP confirmed by Western blot analysis using B1 anti-BCRP - Lane 1: MG 24 hrs; Lane 2: 
MM 24 hrs; MM 48 hrs; MM 72 hrs; Lane 5: PichiaPink-BCRP control; Lane 6: Protein ladder; 
Lane 7: BMGY 24 hrs; Lane 8: BMMY 24 hrs; Lane 9: BMMY 48 hrs; Lane 10: BMMY 72 hrs. 
 
 
 After comparing the performance on the expression of BCRP using the regular MG/MM 
medium and the enriched medium BMGY/BMMY recommended for the PichiaPinkTM, and we 
noticed better results on expression from the enriched medium (figure 6.4 b, lane 10)  
 The time-course analysis was also made on PichiaPink-BCRP cells, and interestingly the 








Figure 6 5: BCRP expression in PichiaPink- time course.  
(A) Culture A – Cells were grown for a total of 24 hours after methanol induction (BMMY). Lane 
1, microsome BCRP control. Lane 2, protein ladder. Lane 3, 24 hrs in BMGY. Lane 4-6, after 
switching to BMMY. Lane 4, 6hrs. Lane 5, 9 hrs. Lane 6, red arrow shows a decrease of BCRP 
expression at 24 hrs. (B) Culture B – Cells were grown for a total of 48 hours after methanol 
induction (BMMY). Lane 1, microsome BCRP control. Lane 2, protein ladder. Lane 3, 24 hrs in 
BMGY. Lane 4-9, after switching to BMMY. Lane 4, 6hrs. Lane 5, 9 hrs. Lane 6, red arrow shows 
a decrease of BCRP expression at 24 hrs. Lane 7, 30 hrs. Lane 8, 33 hrs. Lane 9, 48 hrs, the red 
arrow shows a decrease of expression at this time point. Both cultures were grown for 24 hours in 
a BMGY medium. Then the medium was replaced by BMMY to induce protein expression. 
Aliquots were taken at times indicated for protein expression analysis – 10 µg of lysates were 
applied to each well. 
 
 One major concern during the first step of the purification preparation was the breakage of 
the cells. The established method of breakage using glass beads and a bead beater seemed not to 
be very effective. So,  high-pressure cell rupture was carried out using an Avestin Emulsifle C-5 
homogenizer (Avestin, Inc.). After three passages through the EmulsiFlex, we noticed relatively 
good breakage of the cells on both P. pastoris strains (figure 6.6). 
 Cell breaking strategies that combined the use of Emulsiflex and glass beads/ bead beater 






Figure 6 6: Optimizing BCRP Preparation - Cell breakage.  
Cell breakage after 3 passages of the Emulsiflex Homogenizer at a minimum of 5,000 psi. Arrows 
in the image on the right indicate broken cells. 
 
 The next challenge was solubilization. We noticed that the way the cells were broken 
directly influenced the results during the next steps of purification, i. e. membrane solubilization, 
and affinity chromatography. The solubilization method was also crucial for the success of the 
microsome solubilization. For P-glycoprotein (P-gp), the microsome fraction was first diluted to 
2 mg/ml in low glycerol and low salt buffer containing protease inhibitors, 2-mercaptoethanol, and 
0.6% of the non-ionic detergent n-dodecyl-β-d-maltoside (DDM). The suspension then undergoes 
3-5 cycles of 5 min of sonication in an ice-cold water bath, alternated with 5 min of incubation on 
the ice at the rocker platform.  After this, the suspension is cleared by ultracentrifugation, and the 
supernatant is loaded onto a pre-equilibrated Ni-NTA chromatography column. This procedure 
worked fairly well for Pichia GS115 samples but failed on PichiaPinkTM membranes. Extra 
sonication steps were added using a probe sonicator with 6 cycles of 60-70 watts for 30 seconds 




with the addition of Lyso-PC or E. coli lipids. This solution seemed to be sufficient to solubilize 
the PichiaPinkTM microsome containing BCRP. 
 We still needed to test the combination of breakage and solubilization methods to achieve 
the best possible results (figure 6.6 and 6.7).  
 
 
Figure 6 7: Optimizing BCRP microsome solubilization – test 1 
Three breakage strategies - (1) emulsiflex only; (2) glass beads only; (3) Glass beads + emulsiflex 
- paired with four solubilization procedures - (A) Probe sonicator + water bath sonication + 1% 
DDM + LysoPC; (B) Probe sonicator + water bath sonication + 1% DDM + E. coli lipids; (C) 
water bath sonication + 1% DDM + LysoPC; (D) water bath sonication + 1% DDM + E. coli lipids.  
 
 The Emulsiflex breakage strategy showed the best results along with all solubilization 
procedures. As we faced several technical difficulties keeping the system at 25 psi, we tested if the 
passage samples on the emulsiflex at lower pressure before breakage by glass beads would work 
better than the other conditions (figure 6.8). The strategy did not work and the emulsiflex only, but 






Figure 6 8: Optimizing BCRP microsome solubilization – test 2  
(A) Emulsiflex only: Left, ladder. Middle, solubilization pellet. Right, solubilization supernatant. 
(B) Emusiflex + Glass beads: Left, solubilization pellet. Right, solubilization supernatant.  
 
We had previously optimized the purification protocol for the mouse P-gp (MDR3 Cl – see 
chapter 2) in Pichia pastoris GS115. Later we made modifications for the human P-gp (MDR1 
WT – see chapter 4). For BCRP purification, we improved the solubilization step presenting a 
good amount of BCRP expressed on the supernatant fraction before its loading into the Ni-NTA 
chromatography column (figure 6.9 a and b, lanes 4). We could still observe losses on the 
following fractions, and even though the final elution fraction presented BCRP expression, the 








Figure 6 9: Solubilization and purification trials of BCRP expressed in Pichia pastoris.  
(A) PichiaPink-BCRP - Lane 1: ladder;  Lane 2: microsome (micros); Lane 3: solubilization pellet;  
Lane 4: solubilization supernatant (super); Lane 5: chromatography column first flow-through 
(FT); Lane 6: Chromatography column wash;  Lane 7: Chromatography final fraction Elution. (B) 
Pichia GS115-BCRP - Lane 1: microsome (micros); Lane 2: ladder; Lane 3: solubilization pellet; 
Lane 4: solubilization supernatant (super); Lane 5: Chromatography column first flow-through 
(FT); Lane 6: Chromatography column wash; Lane 7: Chromatography final fraction Elution. 
Coomassie blue staining (top) and western blot (bottom) anti-BCRP (B1 antibody) - 10 µg loaded 
in each well.  
 
 After the inclusion of a second wash with increased imidazole concentration (40 mM), we 
observed that most of the BCRP previously on the elution fraction was then collected on the second 







Figure 6 10: BCRP purification from Pichia pastoris cells. 
(A)PichiaPink-BCRP - Lane 1: microsome; Lane 2: Color Prestained Protein Standard Broad 
Range (10-250 kDa); Lane 3: solubilization pellet; Lane 4: solubilization supernatant; Lane 5: 
chromatography column flow-through first fraction; Lane 6: chromatography column wash 1; 
Lane 7: chromatography column wash 2; Lane 8: chromatography column final elution fraction.  
(B) Pichia GS115: Lane 1: microsome; Lane 2: solubilization pellet; Lane 3: solubilization 
supernatant; Lane 4: Spectra Multicolor Broad Range Protein Ladder (10-260 kDa); Lane 5: 
chromatography column flow-through first fraction; Lane 6: chromatography column wash 1; 
Lane 7: chromatography column wash 2; Lane 8: chromatography column final elution fraction.   
 
 Since BCRP purification could not be achieved using any of the attempted methods, we 
decided to assess whether the ATP hydrolysis activity of BCRP containing membranes could 
potentially be used to assess the BCRP inhibition mechanism by the discovered small-molecule 






Figure 6 11: BCRP activity in PichiaPink membranes.  
Ppink: PichiaPink cells only; PpinkHC: PPink+ pPinkHC vector; PpinkHC-BCRP: PichiaPink-
BCRP; MNT: mitoxantrone. 
 
Since the PichiaPink-BCRP strain showed better overall BCRP expression in crude 
microsome preparations, we used this strain to obtain BCRP containing membrane vesicles 
bypassing the microsome suspension 20 times through a 26G 3/5-gauge syringe. We repeat the 
same procedure with the untransformed PichiaPink and the PichiaPink cells transformed with the 
pPinkHC vector to compare the background activity. Stimulation of BCRP ATPase activity by the 
transport mitoxantrone (MNT) was also assessed. 
Vector alone membranes (Ppink and Ppink HC) showed only very weak ATPase activity 
that was not significantly affected by MNT, while BCRP containing membranes (PpinkHC-BCRP) 
indicated higher ATPase activity that was significantly activated in the presence of the transport 




















































































These results opened the possibilities to assess the inhibitory mechanism of potential BCRP 
inhibitors found in cell culture assays. 
 
6.2.2 BCRP expression in Pichia SDM 1163 
 The difficulties in purifying BCRP from the two strains of Pichia pastoris we had in our 
lab made us look for other options that would give more possibilities to isolate BCRP.  
 We received the Pichia SDM1163 strain containing BCRP from Dr. Mark Rosenberg 
(Oxford University).  The advantage of this clone is the presence of the GFP and FLAG tags and 
the usual HIS tag to facilitate the purification in case we faced similar difficulties as observed for 
the PichiaPinkTM and GS115 cells.  
 Dr. Rosenberg advised the use of zeocin for clone selection. The colonies grew faster in 
plates than the other Pichia strains, so the plates required an exhaustive streak pattern to produce 
single colonies. The SDM1163 cells grew well on the regular MG/MM medium and presented the 
expected BCRP expression after 72 hours of induction in the methanol-based medium.  
 From this step forward, the same difficulties presented by PichiaPink and Pichia GS115 
were met on the Pichia SDM1163 to purify BCRP. The additional tags on this particular clone 
will allow a different approach to achieve BCRP isolation.  
 We wanted to test if the enriched BCRP found in the elution fraction was active for further 
experiments. Initial assays in comparison with the activity of BCRP on the microsomal fraction, 
the other fractions from the chromatography column presented a BCRP that was catalytically 






Figure 6 12: Enriched BCRP Activity Assays.  
Comparison of ATPase hydrolysis activity from BCRP in membrane microsome and Ni-NTA 
chromatography fractions – initial flow-through (FT), wash 1 – W1 (20 mM imidazole), wash 2 – 
W2 (50 mM imidazole), final fraction elution – Elu (200 mM imidazole). 
 
 
6.3 Methods and materials 
6.3.1 E. coli strains: 
 NEB® 5-alpha Competent E. coli (High Efficiency) genotype: F’ proA+B+ 
lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) ∆(ara-leu) 7697 araD139 fhuA ∆lacX74 galK16 galE15 
e14-  Φ80dlacZ∆M15 recA1 relA1 endA1 nupG rpsL (StrR) rph spoT1 ∆(mrr-hsdRMS-mcrBC) 
6.3.2 Agarose gel electrophoresis:  
 Same as described in chapter 3 –Methods and Materials 
6.3.3 Polymerase chain reaction (PCR):  
Same as described in chapter 3 – Methods and Materials 









































6.3.4 Restriction enzyme digestions:  
 Same as described in chapter 3 – Methods and Materials 
6.3.5 Vector Dephosphorylation: 
Same as described in chapter 3 – Methods and Materials 
6.3.6 Ligation:  
Same as described in chapter 3 – Methods and Materials 
6.3.7 Bacterial transformation 
Same as described in chapter 3 – Methods and Materials 
6.3.8 Mini plasmid preparations: 
Same as described in chapter 3 – Methods and Materials 
6.3.9 Midi plasmid preparations: 
Same as described in chapter 3 – Methods and Materials 
6.3.10  DNA purification:  
Same as described in chapter 3 – Methods and Materials 
6.3.11 DNA sequencing: 
Same as described in chapter 3 – Methods and Materials 
6.3.12 Integration of the BCRP gene into GS115 cells by electroporation:   
100 µL of electrocompetent Pichia pastoris cells were added to a 0.2 cm cuvette (BioRad) 
and 15 µg of linearized DNA was added in a volume of less than 25 µL. The cells and DNA were 




with a time constant between 4.68 and 4.8 msec on a BioRad Gene Pulser II. After that, 1 ml of 
ice-cold YPDS media (YPD media + 1M Sorbitol) was added to the cuvette and mixed carefully 
by pipetting. The cuvette was then incubated for 2 hours at 28oC without shaking. The samples 
were then plated on MD/MM plates with volumes of 100 µL, 200 µL, 300 µL, and 400 µL and 
incubated at 28oC for up to 5 days.  
6.3.13  Selection plates: 
6.3.13.1  MD plates: 1.34% YNB; 4x10-5% Biotin; 2% Dextrose; 5% Agar 
6.3.13.2  MM plates: 1.34% YNB; 4x10-5% Biotin; 2%; 1% Methanol; 5% Agar 
6.3.14  Genomic DNA extraction:  
Same as described in chapter 3 – Methods and Materials 
6.3.15 Growth of Pichia pastoris GS115 strain 
Cells were grown initially using the methods previously described for GS115 cells in 
chapter 3. Later, a single colony from a YPD plate (1% Yeast extract, 2% bacto-peptone, 1% 
dextrose, 15g agar/L) was inoculated into 10 ml of YPD medium (1% Yeast extract, 2% bacto-
peptone, 2% dextrose) and incubated at 28oC with shaking to OD600 of ~2.0 (18h). The growth 
proceeded as described on PichiaPinkTM cells with 72 hours methanol induction.  
6.3.16 Growth of PichiaPinkTM:  
Cells were grown using the methods previously described in Invitrogen for PichiaPinkTM 
70, 75, 76, 86, and in chapter 3. In sHORT, A single colony from a YPD agar plate (1.34% Yeast Nitrogen 
Base (YNB), 4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 ml of liquid 
Enriched Minimal Glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% 
YNB, 1% glycerol, 4x10-5% Biotin, 100mM Potassium Phosphate) and incubated at 28oC with 




medium in a 2-liter Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was 
continued (~24h), then the cultures were centrifuged in sterile bottles (6000 rpm for 7 min at 23oC). 
Protein production was induced by switching the carbon source of the medium from glycerol to 
methanol. The cells pellets were resuspended in 1 liter of enriched Minimal Methanol (BMMY) 
medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 4x10-5% Biotin, 0,5% v/v 
methanol, 100mM Potassium Phosphate) in 2-liter Fernbach flasks covered with cheesecloth. 
Incubation continued for 72h with the addition of methanol (1% v/v) at 24 and 48 hours.  The pH 
correction was adjusted to ~6.0 if needed. Cells were finally collected by centrifugation at 6000 
rpm for 7 min at 4oC and resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3 
M Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at a 
concentration of 1g wet cells/ml buffer. The cells were stored at -80oC.  
6.3.17 Growth of Pichia pastoris SMD1163 
After receiving Pichia Pastoris SMD1163 from Dr. Mark F. Rosenberg, Oxford Protein 
Production Factory, Oxford University, cultures were grown first on YPD plates (1% yeast extract, 
2% bacto-peptone, and 1% dextrose). We added a single colony to 10ml of glycerol-based media, 
BMGY (1.34% yeast nitrogen base, 0.00004% biotin, 1% glycerol, 100 mM potassium phosphate, 
1% yeast extract, 2% bacto-peptone, 1mg/mL Zeocin), in a 125ml Erlenmeyer flask for the 
overnight cultures. The initial cultures were transferred to larger flasks containing the same 
glycerol-based medium for 24 hours incubation. We then switched the media from the glycerol-
based media to a methanol-based media, BMMY (1.34% yeast nitrogen base, 0.00004% Biotin, 
0.5% methanol, 100 mM potassium phosphate, 1% yeast extract, 2% bacto-peptone. This was 




72 hours of methanol induction by spinning down the samples in a table-top centrifuge to remove 
the cells from the media.   
6.3.18 Mini microsome preparations from small scale yeast cells growth: 
Same as described in chapter 3 – Methods and Materials 
6.3.19 Microsome preparation from large flasks of yeast cells:  
Microsomes were prepared essentially as described in 86, with the modifications made in 
70, 75, 76. Yeast cultures were grown on a 1–6-liter scale. Sample concentration was diluted using 
A1 Buffer (5% glycerol, 50 mM Tris-HCl, 125 mM NaCl, 10 mM imidazole, 5 mM EDTA, 1 mM 
EGTA, 1 µg/ml Deoxyribonuclease I (DNAse I – Sigma Aldrich) and lysing enzyme (from 
Trichoderma harzianum – Sigma Aldrich). Cell membranes were disrupted using 3 passages 
through an Emulsiflex Homogenizer at 5,000 psi and 10 cycles of glass bead homogenization in a 
bead beater. Cycles alternated between 2 minutes with the bead beater ‘on’ and 6 minutes with it 
‘off.’ The sample was then subjected to differential centrifugation. One low-speed centrifugation 
and two high-speed ultracentrifugations were used to isolate the microsomal membranes (for a 
detailed procedure, see materials and methods in Chapter 3). The microsomes were then frozen at 
-80oC.  
6.3.20 Solubilization of BCRP from Pichia Pastoris GS115 and PichiaPinkTM 
The microsomes were quickly thawed in a circulating water bath set at 28-30oC and then 
eluted to a final concentration of 2 mg microsomal protein/ml with “buffer A2” (20% v/v glycerol, 
50 mM Tris-HCl, pH 8.0 at 4oC, 50 mM NaCl, plus protease inhibitors as follow: 2 µg/ml pepstatin 
A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 1 mM PMSF, 1 mM of 2-Mercaptoethanol and 0.01 
mM TCEP.  To solubilize the Pichia GS115, 0.6% of DDM (n-Dodecyl ß-D-maltoside) was added 




Dodecyl ß-D-maltoside), and a 0.2% PC (phosphotidylcholine) was added initially removed from 
the dilution on later preparations. We also used a probe sonicator (Branson Ultrasonics Sonifier 
250 – Analog Ultrasonic Cell Disruptor/Homogenizer) – 6 cycles of 60-70 watts for 30 seconds at 
4oC (temperatures checked before starting the sonication) prior water-bath sonication for improved 
PichiaPinkTM membrane solubilization. Once the solubilization was achieved, insoluble fractions 
were removed by centrifugation, and the supernatant was applied to a 100 ml Ni-NTA (Qiagen©) 
column for purification using affinity chromatography. 
6.3.21 Solubilization of BCRP from Pichia Pastoris SMD1163 
Pichia SMD1163 membranes were easily solubilized by water-bath sonication. This was 
done through the addition of 1% DDM, 0.01% LysoPC, and protease inhibitors (2 μg/ml Pepstatin 
A, 4 μg/ml Leupeptin, 0.5 μg/ml Chymostatin, 2mM PMSF, 2mM DTT) to Buffer A (20% 
glycerol, 50mM Tris-HCl, pH 8) followed by four cycles of 4 water bath sonication with time in 
between to rest. Once the solubilization was achieved, insoluble fractions were removed by 
centrifugation, and the supernatant was applied to an affinity chromatography column with Ni-
NTA resin (Qiagen) after overnight incubation.  
6.3.22 BCRP Purification from Pichia GS115 and PichiaPinkTM membranes 
The suspension resultant from the solubilization procedures was centrifuged at 20,000 rpm 
for 30 min at 4oC (Beckman Optima LE-80K equipped with Ti 70 or Ti 55.2 rotors) to remove 
insoluble material. The supernatant was then applied to the pre-equilibrated Ni-NTA agarose resin 
(Qiagen) column at a ratio of 100 mg microsomal protein per 1ml packing resin (one bed volume). 
The rest of the procedure was performed at 4oC. The chromatography gel and solubilized protein 
solution were mixed and incubated for 10 minutes before the column was poured (overnight 




The resin with bound P-gp was washed first with 20 bed-volumes of “Column wash buffer 1” (20 
% glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50  mM NaCl, 10 mM Imidazole, supplemented 
with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 % (w/v) lyso-PC/mL buffer), followed by 10 bed-
volume of “Column Wash buffer 2” (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50 
mM NaCl, 20mM-40mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL 
10 % (w/v) lyso-PC/mL buffer). For both washes, the flow-through was ~1 ml/min.  BCRP was 
then eluted with 5 bed-volumes of Elution buffer (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 
@ 4 oC, 50 mM NaCl, 300 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer) 
with a ~0.5 ml/min flow rate. All eluted protein was collected for the next step.  To obtain 
concentrated BCRP, the elution fraction from the Ni-NTA column was concentrated 70- to 100-
fold using Amicon centrifugal filters (Amicon/Millipore Corp., Billerica, MA) with a molecular 
mass cutoff of 50,000 Da. The protein was stored at -80oC.  
6.3.23 BCRP Purification from Pichia SMD1163 membranes 
After the solubilization, the resulting supernatant from the ultracentrifugation was applied to a 
column with Ni-NTA resin (Qiagen) and allowed to incubate overnight before the slurry was 
applied column and let sit for 10 min and allowed to flow through at 2ml/min. Next, the first wash 
(Buffer A, 20mM imidazole, 50mM NaCl) was applied, incubated, and allowed to flow through at 
a slower rate. This was followed by a second wash (Buffer A, 50 mM imidazole, 50 mM NaCl) 
and finally the elution (Buffer A, 250 mM imidazole, 50 mM NaCl). All fractions were 
concentrated in 50 kDa Amicon filters, and the protein was stored at -80oC. 
6.3.24 ATPase activity assay using P. pastoris membranes:  




6.3.25 Western Blot analysis:  
Same as described in chapter 3 – Materials and Methods, with the following modification: 
1:1000 dilution in primary monoclonal antibody B1 – mouse anti-ABCG2 (sc-377176, Santa Cruz 
Biotechnology) for 1 hour at room temperature or overnight at 4oC in a rocking platform.  
 
6.4 Discussion 
Relatively large quantities of purified BCRP are desirable to perform biochemical, kinetic, 
and biophysical analyses of inhibitors of BCRP for the evaluation of the inhibition mechanism of 
the new drug-like compounds we wanted to test in our lab.  
A new human BCRP clone was designed with optimized codon usage for translation and 
expression in P. pastoris. It was successfully integrated into two strains of Pichia pastoris, 
PichiaPinkTM and GS115, and BCRP expression was observed in both strains (figures 6.2 and 6.4). 
Expression of BCRP was significantly higher in PichiaPinkTM at nine hours after induction. Initial 
ATP hydrolysis assays on PichiaPink-BCRP membranes (figure 6.3) indicated that the protein 
expressed was catalytically active and that ATP hydrolysis activity could be stimulated by the 
known BCRP transport substrate Hoechst 33342 140, 147. 
Challenges to purify BCRP from heterologous membranes were previously reported 148. 
Optimization of the expression system PichiaPinkTM was required in each step of the purification, 
including the cell growth. Most of the modifications made for PichiaPink-BCRP cells improved 
GS115-BCRP and KM71H-MDR1 (P-gp) purification conditions.  
As seen in figure 6.4, BCRP expression in PichiaPink cells was highest at 6-9 hours after 




may be due to the high alcohol oxidase production and depletion of the nutrients of the media. We 
tried to “feed” the cells with additional methanol at different time intervals before 24 hours, but 
the cells continued to die (data not shown). We determine the optimal time to harvest the 
PichiaPink cells to be at 9 hours after induction with methanol, suggesting a surprisingly fast onset 
of protein production in the PichiaPinkTM strains. Protein expression was confirmed by Western 
blot analysis using both anti-BCRP and anti-His antibodies. ATP hydrolysis assays indicated that 
the protein expressed was catalytically active and that the ATP hydrolysis activity could be 
stimulated by the BCRP transport substrate, Hoechst 33342 (figure 6.11).    
Pichia GS115 required less optimization on the steps before the purification. Large scale 
cultures using the enriched medium recommended for PichiaPinkTM growth resulted in a better 
BCRP expression at 72 hours after methanol induction than the previous recommenced minimal 
glycerol/methanol medium (figure 6.4 b).  We decided to also use the enriched culture medium on 
the next grows of GS115-BCRP. Even though the expression levels of BCRP in GS115 had 
improved, it was still lower than what was achieved by PichiaPink-BCRP. As we were still facing 
difficulties in isolating BCRP from PichiaPink membranes, we decided to try and optimize 
conditions for both strains, hoping that GS115 membranes would be easier to work with. While 
solubilization for GS115 membranes was deemed adequate, optimization efforts were needed for 
better protein expression and higher yields during purification.  
Microsome and purification protocols as originally described by Bai et al. 82 for P-
glycoprotein in Pichia pastoris were initially used for BCRP purification from PichiaPinkTM and 
Pichia GS115. We noticed some difficulties from the beginning: the cells were not well broken. 
The microsome yield was low compared with the regular preparations made with P-gp, where the 




intensity. Unfortunately, the same strategy did not seem to work well in our attempts for BCRP 
membranes. In addition to that, the final microsomal fraction was also not well solubilized in the 
first step of protein purification. We thought both steps could be related, so we ran trials of each 
condition independently. 
We improved the breakage by changing the volume of the beads added and the ratio mass 
of cells/total volume. We also added deoxyribonuclease I (DNAse I) to reduce sample viscosity 
due to the release of nucleic acids and the lysing enzyme from Trichoderma harzianum to 
hydrolyze yeast cells wall oligosaccharides. We increased the breakage cycles from 7 to 9 cycles 
of 2 minutes of breakage and 2 minutes resting on ice. These changes improved the overall cell 
breakage and the microsome yield, but we still faced poor solubilization in later stages (figure 6.7). 
We hypothesized that the breakage using glass beads could break the membrane so that they would 
form sheets that would stack together, preventing the solubilization from working properly. To test 
this hypothesis, we used an Emulsiflex – Avestin C5 High-Pressure Homogenizer (Avestin, Inc.) 
to produce membrane vesicles instead of membrane sheets. It has an additional advantage over the 
well-known French press. It can hold large sample volumes, process samples in continuous passes, 
achieve higher pressure, and process relatively viscous samples. The recommended pressure 
reported for Pichia was 22000-25000 psi with multiple passages. We tested the system comparing 
samples with one, two, and three passages, with the latter being the most successful on cells 
breakage (figure 6.6). When the system worked properly, it resulted in three times better cell 
breakage than glass beads and bead beaters.  However, after only very few uses of the 
homogenizer, the system clogged and did not reach the pressure needed to disrupt the cells.  
As membrane solubilization is a critical step for protein purification, we also tested 




the addition of lyso-PC and the DDM to dilute the samples, the method of choice for the P-gp 
purification, was not successful. Fos-choline-16 was reported to facilitate the solubilization of 
insect cells containing BCRP 148-151. Most of those studies aimed to isolate BCRP for structural 
studies, so protein activity was a secondary concern. Telbizs et al. (2013)152 described a successful 
Sf9 cells solubilization using a lipid/detergent mixture (1% DDM and 0.4% E. coli lipid extract). 
They found that BCRP was inactive in detergent-solubilized form using different detergents. Still, 
the ATPase activity could be preserved when lipids were used together with DDM in the 
solubilization except when the detergent used was Fos-choline-16, when the ATPase activity was 
abolished possibly for irreversible dissociation of the homodimers. With this information in mind, 
we decided not to go further with any tests using Fos-choline-16 but try E. coli lipid extract 
compared to the Lyso-PC already established in our methods. 
Initially, we start increasing the DDM concentration and added extra cycles of sonication 
at the water bath with no success on the solubilization. We then thought about increase the 
sonication strength by using a sonicator with a probe (see Material and Methods, section 6.3.21) 
before the water bath sonication. We noticed clearance of the suspension after each cycle. We 
combined this new sonication procedure with different combination of lipid/detergent usage 
(DDM, E. coli lipid extract and Lyso-PC) and cells breakage methods: (A) Probe sonicator + water 
bath sonication + 1% DDM + LysoPC; (B) Probe sonicator + water bath sonication + 1% DDM + 
E. coli lipids; (C) water bath sonication + 1% DDM + LysoPC; (D) water bath sonication + 1% 
DDM + E. coli lipids. 
For all conditions tested, using only the Emulsiflex for cell breakage was better for the 
subsequent solubilization step, as shown in figure 6.7. Moreover, the solubilization was 




combination DDM + E. coli lipids. Combining techniques, including cell breakage and 
solubilization conditions, achieved a consistent 60% membrane solubilization of PichiaPink-
BCRP microsomes. However, using only the Emulsiflex as a cell breakage method required 
excessive time as it suffered from some technical difficulties (i.e., achieving necessary pressures 
was difficult), which made it hard to maintain the quality and reproducibility of the method. The 
time involved was problematic for protein stability. As the pressures were hard to maintain 
consistently at 25,000 psi, we decided to run 3 cycles at 5,000 psi on the Emulsiflex followed by 
glass bead breakage. Subjecting the cells to the Emulsiflex homogenization before glass bead 
breakage allowed significant improvements in the purification of BCRP. When we compared the 
solubilization results of this combined with the performance of the Emulsiflex only (figure 6.8), 
the adjustment was somewhat satisfactory. Still, it worked better than the option of glass beads or 
glass beads + Emulsiflex (figure 6.7). 
Once the successful microsomal solubilization was established, the next step was to 
optimize the conditions for purification on the Ni-NTA affinity chromatography. Insoluble 
fractions from solubilization were removed by centrifugation, and the supernatant was applied to 
a Ni-NTA column for purification.  
In our first attempt, we observed loss of BCRP in each fraction of the purification. Even 
though we were able to collect some BCRP from the final elution, it was not purified as we could 
see many contaminants on the final fraction (figure 6.9).  Changes in imidazole concentration in 
the binding buffer and changes in pH as well as including more wash steps did not improve the 
outcome significantly 
McDevitt et al. 148, 149 reported difficulties in isolating detergent solubilized protein 




The suggestion was that the histidine-tag of BCRP might be partially occluded since 
immunoblotting confirmed the tags were intact.  
In summary, microsome preparations with high expression of BCRP in PichiaPink and 
GS115 cells were achieved. Solubilization was also improved, however, and BCRP purification 
proved challenging. For this reason, crude microsome preparations were formed into vesicles and 
used for activity assays (figure 6.11). We wanted to know if we could still use the membranes for 
activity assays and test the effects of the new drug-like compounds on BCRP ATPase hydrolysis 
activity. 
ATPase activity of BCRP expressed in membranes has been largely performed by others 
146, 153, 154. As PichiaPink-BCRP cells presented higher protein expression, we decided to start our 
trials with these membranes to analyze if the BCRP was catalytically active. We compared 
PichiaPink-BCRP membranes with PichiaPink membranes in different backgrounds: PichiaPink 
cells only and PichiaPink-pPinkHC (integration of the cloning vector) (figure 6.11).  We also 
wanted to verify if the BCRP ATPase activity could be stimulated by the substrate mitoxantrone 
(MNT).  
Since the activity of the PichiaPink-BCRP was increased when compared with both 
backgrounds and was stimulated by a transport substrate, we assume biologically active BCRP 
was present. With these results, we were optimistic that we would be able to use membrane assays 
to further tests of drug inhibition in the future.  
For some mechanistic studies, for example, evaluating the effect of the potential inhibitor 
on ATP binding using electron spin resonance spectroscopy, purified protein in mixed micelles or 
nanodisc assembled proteins is required. To date, all efforts to purify BCRP to a level that allows 




However, the presence of different tags on the SDM1163-BCRP that we received in 
collaboration with Mark Rosenberg (Oxford University) may present other alternatives to the 
purification procedures describe here.  
 Much effort was put into this project as we still could not test any of the potential BCRP 
inhibitors to corroborate the cell culture findings. We hope that optimizing the conditions and the 
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